CINXE.COM

<!DOCTYPE html> <html class="client-nojs" lang="en" dir="ltr"> <head> <meta charset="UTF-8"/> <title>Breast cancer - Citizendium</title> <script>document.documentElement.className="client-js";RLCONF={"wgBreakFrames":false,"wgSeparatorTransformTable":["",""],"wgDigitTransformTable":["",""],"wgDefaultDateFormat":"dmy","wgMonthNames":["","January","February","March","April","May","June","July","August","September","October","November","December"],"wgRequestId":"5744b3c344609177347c205d","wgCSPNonce":false,"wgCanonicalNamespace":"","wgCanonicalSpecialPageName":false,"wgNamespaceNumber":0,"wgPageName":"Breast_cancer","wgTitle":"Breast cancer","wgCurRevisionId":979686,"wgRevisionId":979686,"wgArticleId":26259,"wgIsArticle":true,"wgIsRedirect":false,"wgAction":"view","wgUserName":null,"wgUserGroups":["*"],"wgCategories":["Health Sciences tag","Biology tag","Suggestion Bot Tag","Pages using PMID magic links","CZ Live","Health Sciences Workgroup","Biology Workgroup","Oncology Subgroup","Obstetrics and gynecology Subgroup","Articles written in British English","All Content","Health Sciences Content","Biology Content","Oncology tag", "Obstetrics and gynecology tag","Internal articles including external material","Flagged for Review","Pages with too many expensive parser function calls"],"wgPageContentLanguage":"en","wgPageContentModel":"wikitext","wgRelevantPageName":"Breast_cancer","wgRelevantArticleId":26259,"wgIsProbablyEditable":false,"wgRelevantPageIsProbablyEditable":false,"wgRestrictionEdit":[],"wgRestrictionMove":[],"wgPageFormsTargetName":null,"wgPageFormsAutocompleteValues":[],"wgPageFormsAutocompleteOnAllChars":false,"wgPageFormsFieldProperties":[],"wgPageFormsCargoFields":[],"wgPageFormsDependentFields":[],"wgPageFormsCalendarValues":[],"wgPageFormsCalendarParams":[],"wgPageFormsCalendarHTML":null,"wgPageFormsGridValues":[],"wgPageFormsGridParams":[],"wgPageFormsContLangYes":null,"wgPageFormsContLangNo":null,"wgPageFormsContLangMonths":[],"wgPageFormsHeightForMinimizingInstances":800,"wgPageFormsShowOnSelect":[],"wgPageFormsScriptPath":"/wiki/extensions/PageForms","edgValues":null, "wgPageFormsEDSettings":null,"wgAmericanDates":false,"wgVector2022PreviewPages":[],"wgMediaViewerOnClick":true,"wgMediaViewerEnabledByDefault":true,"wgPopupsFlags":4};RLSTATE={"site.styles":"ready","user.styles":"ready","user":"ready","user.options":"loading","ext.cite.styles":"ready","skins.vector.styles.legacy":"ready"};RLPAGEMODULES=["ext.cite.ux-enhancements","site","mediawiki.page.ready","mediawiki.toc","skins.vector.legacy.js","mmv.head","mmv.bootstrap.autostart","ext.gadget.charinsert","ext.popups"];</script> <script>(RLQ=window.RLQ||[]).push(function(){mw.loader.implement("user.options@12s5i",function($,jQuery,require,module){mw.user.tokens.set({"patrolToken":"+\\","watchToken":"+\\","csrfToken":"+\\"});});});</script> <link rel="stylesheet" href="/wiki/load.php?lang=en&modules=ext.cite.styles%7Cskins.vector.styles.legacy&only=styles&skin=vector"/> <script async="" src="/wiki/load.php?lang=en&modules=startup&only=scripts&raw=1&skin=vector"></script> <meta name="ResourceLoaderDynamicStyles" content=""/> <link rel="stylesheet" href="/wiki/load.php?lang=en&modules=site.styles&only=styles&skin=vector"/> <meta name="generator" content="MediaWiki 1.39.5"/> <meta name="format-detection" content="telephone=no"/> <meta name="viewport" content="width=1000"/> <link rel="icon" href="/images/favicon1.ico"/> <link rel="search" type="application/opensearchdescription+xml" href="/wiki/opensearch_desc.php" title="Citizendium"/> <link rel="EditURI" type="application/rsd+xml" href="https://citizendium.org/wiki/api.php?action=rsd"/> <link rel="license" href="https://creativecommons.org/licenses/by-nc-sa/4.0/"/> <link rel="alternate" type="application/atom+xml" title="Citizendium Atom feed" href="/wiki/index.php?title=Special:RecentChanges&feed=atom"/> <script async src="https://www.googletagmanager.com/gtag/js?id=G-W7ML9SNPXT"></script> <script> window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-W7ML9SNPXT'); </script> </head> <body class="mediawiki ltr sitedir-ltr mw-hide-empty-elt ns-0 ns-subject page-Breast_cancer rootpage-Breast_cancer skin-vector action-view skin-vector-legacy vector-feature-language-in-header-enabled vector-feature-language-in-main-page-header-disabled vector-feature-language-alert-in-sidebar-disabled vector-feature-sticky-header-disabled vector-feature-sticky-header-edit-disabled vector-feature-table-of-contents-disabled vector-feature-visual-enhancement-next-disabled"><div id="mw-page-base" class="noprint"></div> <div id="mw-head-base" class="noprint"></div> <div id="content" class="mw-body" role="main"> <a id="top"></a> <div id="siteNotice"></div> <div class="mw-indicators"> </div> <h1 id="firstHeading" class="firstHeading mw-first-heading">Breast cancer</h1> <div id="bodyContent" class="vector-body"> <div id="siteSub" class="noprint">From Citizendium</div> <div id="contentSub"></div> <div id="contentSub2"></div> <div id="jump-to-nav"></div> <a class="mw-jump-link" href="#mw-head">Jump to navigation</a> <a class="mw-jump-link" href="#searchInput">Jump to search</a> <div id="mw-content-text" class="mw-body-content mw-content-ltr" lang="en" dir="ltr"><div class="mw-parser-output"><div style="float:right;"><div style="position:relative; top: -20px;"> <div style="cursor: pointer" onClick="return addthis_open(this, '', 'https://en.citizendium.org/wiki/Breast cancer', 'Breast cancer')" onmouseout="addthis_close()"><img src="//s9.addthis.com/button1-share.gif" width="125" height="16" border="0" alt="" /></div>   <script type="text/javascript"> addthis_pub = 'citizendium'; addthis_logo = ''; addthis_logo_color = ''; addthis_logo_background = ''; addthis_brand = 'Citizendium'; addthis_options = ''; addthis_offset_top = ''; addthis_offset_left = ''; </script><script type="text/javascript" src="//s7.addthis.com/js/152/addthis_widget.js"></script>  </div></div><div align="left" style="background-color: #cccccc; margin:0.5em;position:relative;"> <table class="noprint" width="100%" border="0" cellpadding="4" cellspacing="0" style="background:#f3f3f3"> <tbody><tr> <td rowspan="2" width="2px" valign="top" align="left" style="background:#C4D2DF; border-left:1px solid #aaaaaa; border-bottom:1px solid #aaaaaa; border-top:1px solid #aaaaaa; border-right:1px solid #aaaaaa;"><a href="/wiki/File:Statusbar2.png" class="image" title="This article is developing and not approved."><img alt="This article is developing and not approved." src="/wiki/images/4/4f/Statusbar2.png" decoding="async" width="12" height="59" data-file-width="12" data-file-height="59" /></a> </td> <td align="center" bgcolor="#C4D2DF" style="border-bottom:1px solid #C4D2DF; white-space: nowrap; border-top:1px solid #aaaaaa; border-right:1px solid #aaaaaa; font-size:0.9em;"><a class="mw-selflink selflink">Main Article</a> </td> <td align="center" bgcolor="#CCCCCC" style="white-space: nowrap; border-bottom:1px solid #aaaaaa; border-top:1px solid #aaaaaa; border-right:1px solid #aaaaaa; font-size:0.9em;"><a href="/wiki/Talk:Breast_cancer" title="Talk:Breast cancer">Discussion</a> </td> <td align="center" bgcolor="#CCCCCC" style="white-space: nowrap; border-bottom:1px solid #aaaaaa; border-top:1px solid #aaaaaa; border-right:1px solid #aaaaaa; font-size:0.9em;"><a href="/wiki/Breast_cancer/Related_Articles" title="Breast cancer/Related Articles">Related Articles </a> <a href="/wiki/CZ:Related_Articles" title="CZ:Related Articles">[?]</a> </td> <td align="center" bgcolor="#CCCCCC" style="white-space: nowrap; border-bottom:1px solid #aaaaaa; border-top:1px solid #aaaaaa; border-right:1px solid #aaaaaa; font-size:0.9em;"><a href="/wiki/Breast_cancer/Bibliography" title="Breast cancer/Bibliography">Bibliography </a> <a href="/wiki/CZ:Bibliography" title="CZ:Bibliography">[?]</a> </td> <td align="center" bgcolor="#CCCCCC" style="white-space: nowrap; border-bottom:1px solid #aaaaaa; border-top:1px solid #aaaaaa; border-right:1px solid #aaaaaa; font-size:0.9em;"><a href="/wiki/Breast_cancer/External_Links" title="Breast cancer/External Links">External Links </a> <a href="/wiki/CZ:External_Links" title="CZ:External Links">[?]</a> </td> <td align="center" bgcolor="#CCCCCC" style="white-space: nowrap; border-bottom:1px solid #aaaaaa; border-top:1px solid #aaaaaa; border-right:1px solid #aaaaaa; font-size:0.9em;"><a rel="nofollow" class="external text" href="http://en.citizendium.org/wiki?action=edit&preload=Template%3ACitable_Version_start&title=Breast_cancer/Citable_Version">Citable Version </a> <a href="/wiki/CZ:Citable_Version" title="CZ:Citable Version">[?]</a> </td> <td align="center" bgcolor="#CCCCCC" style="white-space: nowrap; border-bottom:1px solid #aaaaaa; border-top:1px solid #aaaaaa; border-right:1px solid #aaaaaa; font-size:0.9em;"><div style="position:relative; width:14px; height:14px; overflow:hidden;"><div style="position:absolute; font-size:14px; overflow:hidden; line-height:14px; letter-spacing:14px;"><a href="/wiki/CZ:Subpages" title="CZ:Subpages">   </a></div><a href="/wiki/File:Subpages.png" class="image" title="CZ:Subpages"><img alt="CZ:Subpages" src="/wiki/images/thumb/1/1f/Subpages.png/14px-Subpages.png" decoding="async" width="14" height="14" srcset="/wiki/images/1/1f/Subpages.png 1.5x" data-file-width="17" data-file-height="17" /></a></div><div style="position:relative; width:14px; height:14px; overflow:hidden;"><div style="position:absolute; font-size:14px; overflow:hidden; line-height:14px; letter-spacing:14px;"><a href="/wiki/Template:Breast_cancer/Metadata" title="Template:Breast cancer/Metadata">   </a></div><a href="/wiki/File:Metadata.png" class="image" title="Template:Breast cancer/Metadata"><img alt="Template:Breast cancer/Metadata" src="/wiki/images/thumb/4/4f/Metadata.png/14px-Metadata.png" decoding="async" width="14" height="14" srcset="/wiki/images/4/4f/Metadata.png 1.5x" data-file-width="17" data-file-height="17" /></a></div> </td> <td width="100%" style="background-color: #f3f3f3; border-bottom:1px solid #aaaaaa">  </td></tr> <tr> <td height="40px" colspan="20" style="background:#C4D2DF; padding: 2px 2px 2px 2px; border-right:1px solid #aaaaaa; border-bottom:1px solid #aaaaaa"> <table align="right" border="0" cellpadding="2" cellspacing="0"> <tbody><tr> <td><div class="plainlinks plainlinksneverexpand" style="position:relative; width:17px; height:17px; overflow:hidden; text-decoration:none;"><div style="position:absolute; font-size:17px; overflow:hidden; line-height:17px; letter-spacing:17px;"><a rel="nofollow" class="external text" href="https://en.citizendium.org/wiki/index.php?title=Breast_cancer&printable=yes">   </a></div><a href="/wiki/File:Print_button.png" class="image" title="https://en.citizendium.org/wiki/index.php?title=Breast_cancer&printable=yes"><img alt="https://en.citizendium.org/wiki/index.php?title=Breast_cancer&printable=yes" src="/wiki/images/thumb/0/07/Print_button.png/17px-Print_button.png" decoding="async" width="17" height="17" srcset="/wiki/images/thumb/0/07/Print_button.png/26px-Print_button.png 1.5x, /wiki/images/thumb/0/07/Print_button.png/34px-Print_button.png 2x" data-file-width="45" data-file-height="45" /></a></div> </td></tr></tbody></table>This editable Main Article is under development and subject to a <a href="/wiki/CZ:Disclaimer" title="CZ:Disclaimer">disclaimer</a>. <div style="float:right; margin: .1em .5em;">[<a rel="nofollow" class="external text" href="https://citizendium.org/wiki/index.php?title=Breast_cancer&action=edit&section=0">edit intro</a>]</div> </td></tr></tbody></table></div> <div style="float:right; clear:right; margin:0 0 0.5em 0.3em; padding:0.5em 0 0.8em 1.4em;"><div id="toc" class="toc" role="navigation" aria-labelledby="mw-toc-heading"><input type="checkbox" role="button" id="toctogglecheckbox" class="toctogglecheckbox" style="display:none" /><div class="toctitle" lang="en" dir="ltr"><h2 id="mw-toc-heading">Contents</h2><label class="toctogglelabel" for="toctogglecheckbox"></label></div> <ul> <li class="toclevel-1 tocsection-1"><a href="#History">1 History</a></li> <li class="toclevel-1 tocsection-2"><a href="#Classification">2 Classification</a></li> <li class="toclevel-1 tocsection-3"><a href="#Pathology">3 Pathology</a> <ul> <li class="toclevel-2 tocsection-4"><a href="#Metastasis">3.1 Metastasis</a></li> </ul> </li> <li class="toclevel-1 tocsection-5"><a href="#Diagnosis">4 Diagnosis</a> <ul> <li class="toclevel-2 tocsection-6"><a href="#Symptoms">4.1 Symptoms</a></li> <li class="toclevel-2 tocsection-7"><a href="#Physical_examination">4.2 Physical examination</a></li> <li class="toclevel-2 tocsection-8"><a href="#Pathological_examination">4.3 Pathological examination</a></li> </ul> </li> <li class="toclevel-1 tocsection-9"><a href="#Epidemiologic_risk_factors_and_etiology">5 Epidemiologic risk factors and etiology</a> <ul> <li class="toclevel-2 tocsection-10"><a href="#Age">5.1 Age</a></li> <li class="toclevel-2 tocsection-11"><a href="#Gender">5.2 Gender</a></li> <li class="toclevel-2 tocsection-12"><a href="#Heredity">5.3 Heredity</a></li> <li class="toclevel-2 tocsection-13"><a href="#Diet">5.4 Diet</a></li> <li class="toclevel-2 tocsection-14"><a href="#Alcohol">5.5 Alcohol</a></li> <li class="toclevel-2 tocsection-15"><a href="#Obesity">5.6 Obesity</a></li> <li class="toclevel-2 tocsection-16"><a href="#Radiation">5.7 Radiation</a></li> <li class="toclevel-2 tocsection-17"><a href="#Late_pregnancy">5.8 Late pregnancy</a></li> <li class="toclevel-2 tocsection-18"><a href="#Hormones">5.9 Hormones</a></li> <li class="toclevel-2 tocsection-19"><a href="#Environmental_causes">5.10 Environmental causes</a> <ul> <li class="toclevel-3 tocsection-20"><a href="#Tobacco">5.10.1 Tobacco</a></li> <li class="toclevel-3 tocsection-21"><a href="#Radiation_2">5.10.2 Radiation</a></li> <li class="toclevel-3 tocsection-22"><a href="#Impact_of_environmental_estrogenic_mimics">5.10.3 Impact of environmental estrogenic mimics</a></li> </ul> </li> <li class="toclevel-2 tocsection-23"><a href="#Viral_breast_cancer_pathogenesis_research">5.11 Viral breast cancer pathogenesis research</a></li> <li class="toclevel-2 tocsection-24"><a href="#Factors_with_minimal_impact_on_breast_cancer_risk">5.12 Factors with minimal impact on breast cancer risk</a> <ul> <li class="toclevel-3 tocsection-25"><a href="#Abortion">5.12.1 Abortion</a></li> <li class="toclevel-3 tocsection-26"><a href="#Deodorants">5.12.2 Deodorants</a></li> <li class="toclevel-3 tocsection-27"><a href="#Fertility_treatments">5.12.3 Fertility treatments</a></li> <li class="toclevel-3 tocsection-28"><a href="#Phytoestrogens_and_soy">5.12.4 Phytoestrogens and soy</a></li> </ul> </li> </ul> </li> <li class="toclevel-1 tocsection-29"><a href="#Prevention_in_high-risk_individuals">6 Prevention in high-risk individuals</a> <ul> <li class="toclevel-2 tocsection-30"><a href="#Prophylactic_oophorectomy">6.1 Prophylactic oophorectomy</a></li> <li class="toclevel-2 tocsection-31"><a href="#Managing_side_effects_of_prophylactic_oophorectomy">6.2 Managing side effects of prophylactic oophorectomy</a> <ul> <li class="toclevel-3 tocsection-32"><a href="#Hormonal_treatments">6.2.1 Hormonal treatments</a></li> </ul> </li> <li class="toclevel-2 tocsection-33"><a href="#Prophylactic_mastectomy">6.3 Prophylactic mastectomy</a></li> <li class="toclevel-2 tocsection-34"><a href="#Medications">6.4 Medications</a> <ul> <li class="toclevel-3 tocsection-35"><a href="#Selective_estrogen_receptor_modulators_(SERMs)">6.4.1 Selective estrogen receptor modulators (SERMs)</a></li> </ul> </li> </ul> </li> <li class="toclevel-1 tocsection-36"><a href="#Screening">7 Screening</a> <ul> <li class="toclevel-2 tocsection-37"><a href="#Breast_self-examination">7.1 Breast self-examination</a></li> <li class="toclevel-2 tocsection-38"><a href="#Clinical_breast_examination">7.2 Clinical breast examination</a></li> <li class="toclevel-2 tocsection-39"><a href="#X-ray_mammography">7.3 X-ray mammography</a> <ul> <li class="toclevel-3 tocsection-40"><a href="#Screening_women_aged_40_to_50">7.3.1 Screening women aged 40 to 50</a></li> <li class="toclevel-3 tocsection-41"><a href="#False_positives">7.3.2 False positives</a></li> <li class="toclevel-3 tocsection-42"><a href="#Overdiagnosis">7.3.3 Overdiagnosis</a></li> <li class="toclevel-3 tocsection-43"><a href="#Source_of_controversy">7.3.4 Source of controversy</a></li> </ul> </li> <li class="toclevel-2 tocsection-44"><a href="#Breast_MRI">7.4 Breast MRI</a></li> <li class="toclevel-2 tocsection-45"><a href="#Breast_ultrasound">7.5 Breast ultrasound</a></li> <li class="toclevel-2 tocsection-46"><a href="#Genetic_testing">7.6 Genetic testing</a></li> </ul> </li> <li class="toclevel-1 tocsection-47"><a href="#Prognosis">8 Prognosis</a> <ul> <li class="toclevel-2 tocsection-48"><a href="#Staging">8.1 Staging</a></li> <li class="toclevel-2 tocsection-49"><a href="#Cell_receptor_proteins">8.2 Cell receptor proteins</a></li> <li class="toclevel-2 tocsection-50"><a href="#Gene_expression_profiling">8.3 Gene expression profiling</a></li> </ul> </li> <li class="toclevel-1 tocsection-51"><a href="#Treatment">9 Treatment</a> <ul> <li class="toclevel-2 tocsection-52"><a href="#Surgery">9.1 Surgery</a></li> <li class="toclevel-2 tocsection-53"><a href="#Radiation_therapy">9.2 Radiation therapy</a> <ul> <li class="toclevel-3 tocsection-54"><a href="#Indications_for_radiation">9.2.1 Indications for radiation</a></li> <li class="toclevel-3 tocsection-55"><a href="#Types_of_radiotherapy">9.2.2 Types of radiotherapy</a></li> <li class="toclevel-3 tocsection-56"><a href="#Side_effects_of_radiation_therapy">9.2.3 Side effects of radiation therapy</a></li> </ul> </li> <li class="toclevel-2 tocsection-57"><a href="#Systemic_therapy">9.3 Systemic therapy</a> <ul> <li class="toclevel-3 tocsection-58"><a href="#Chemotherapy">9.3.1 Chemotherapy</a> <ul> <li class="toclevel-4 tocsection-59"><a href="#Nonhormonal">9.3.1.1 Nonhormonal</a></li> <li class="toclevel-4 tocsection-60"><a href="#Hormonal_treatment">9.3.1.2 Hormonal treatment</a></li> </ul> </li> <li class="toclevel-3 tocsection-61"><a href="#Biologic_therapies">9.3.2 Biologic therapies</a> <ul> <li class="toclevel-4 tocsection-62"><a href="#Targeted_therapy">9.3.2.1 Targeted therapy</a></li> <li class="toclevel-4 tocsection-63"><a href="#Antiangiogenic_therapy">9.3.2.2 Antiangiogenic therapy</a></li> </ul> </li> </ul> </li> </ul> </li> <li class="toclevel-1 tocsection-64"><a href="#Follow-up_surveillance">10 Follow-up surveillance</a></li> <li class="toclevel-1 tocsection-65"><a href="#Breast_cancer_in_males">11 Breast cancer in males</a></li> <li class="toclevel-1 tocsection-66"><a href="#Psychological_aspects_of_breast_cancer_diagnosis_and_treatment">12 Psychological aspects of breast cancer diagnosis and treatment</a></li> <li class="toclevel-1 tocsection-67"><a href="#Attribution">13 Attribution</a></li> <li class="toclevel-1 tocsection-68"><a href="#References">14 References</a></li> </ul> </div> </div> <table class="infobox"> <tbody><tr> <th colspan="2" class="caption" style="width:auto;">Breast cancer </th></tr> <tr> <th>ICD-10 </th> <td><a rel="nofollow" class="external text" href="http://www.who.int/classifications/apps/icd/icd10online/?gf80.htm+f840">ICD10 F84.0-F84.1</a> </td></tr> <tr> <th>ICD-9 </th> <td><a rel="nofollow" class="external text" href="http://www.icd9data.com/getICD9Code.ashx?icd9=174">174</a> -<a rel="nofollow" class="external text" href="http://www.icd9data.com/getICD9Code.ashx?icd9=175">175</a> </td></tr> <tr> <th>OMIM </th> <td><a rel="nofollow" class="external text" href="http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=114480">114480</a> </td></tr> <tr> <th>MedlinePlus </th> <td><a rel="nofollow" class="external text" href="http://www.nlm.nih.gov/medlineplus/ency/article/000913.htm">000913</a> </td></tr> </tbody></table> Breast cancer is a <a href="/wiki/Cancer" title="Cancer">cancer</a> that originates in the glandular <a href="/wiki/Breast" title="Breast">breast</a> tissue. Worldwide, it is the fifth most common cause of cancer death (after <a href="/wiki/Lung_cancer" title="Lung cancer">lung cancer</a>, <a href="/wiki/index.php?title=Stomach_cancer&action=edit&redlink=1" class="new" title="Stomach cancer (page does not exist)">stomach cancer</a>, <a href="/wiki/index.php?title=Liver_cancer&action=edit&redlink=1" class="new" title="Liver cancer (page does not exist)">liver cancer</a>, and <a href="/wiki/index.php?title=Colon_cancer&action=edit&redlink=1" class="new" title="Colon cancer (page does not exist)">colon cancer</a>). In 2005, breast cancer caused 502,000 deaths (7% of cancer deaths; almost 1% of all deaths) worldwide.<a href="#cite_note-who_fact_sheet-1">[1]</a> Among women worldwide, breast cancer is the most common cancer.<a href="#cite_note-who_fact_sheet-1">[1]</a> Decade by decade, medical understanding of breast cancer, and treatments available for it, have grown. As of 2024, it is often possible for doctors to isolate exactly which kind among many possible cancers the patient has, and there are some newer targeted therapies for certain kinds. In the U.S.A., breast cancer is the most prevalent cancer in women, and the second most common cause of cancer death in women (after lung cancer). In 2007, breast cancer is expected to cause 40,910 deaths (7% of cancer deaths; almost 2% of all deaths) in the U.S.A.<a href="#cite_note-acs_cancer_facts_2007-2">[2]</a><a href="#cite_note-acs_bc_key_stats-3">[3]</a> Women in the U.S.A. have a 1 in 8 lifetime chance of developing invasive breast cancer and a 1 in 33 chance of breast cancer causing their death.<a href="#cite_note-acs_bc_key_stats-3">[3]</a><a href="#cite_note-pmid19920274-4">[4]</a> The number of cases has significantly increased since the 1970s, a phenomenon partly blamed on modern lifestyles in the Western world.<a href="#cite_note-indy-5">[5]</a><a href="#cite_note-6">[6]</a> Because the breast is composed of identical tissues in males and females, breast cancer also occurs in males, though it is less common.<a href="#cite_note-Dave-7">[7]</a> <h2>History</h2> Breast cancer may be one of the oldest known forms of cancer tumors in humans. The oldest description of cancer (although the term cancer was not used) was discovered in Egypt and dates back to approximately 1600 BC. The <a href="/wiki/index.php?title=Edwin_Smith_Papyrus&action=edit&redlink=1" class="new" title="Edwin Smith Papyrus (page does not exist)">Edwin Smith Papyrus</a> describes 8 cases of tumors or ulcers of the breast that were treated by <a href="/wiki/index.php?title=Cauterization&action=edit&redlink=1" class="new" title="Cauterization (page does not exist)">cauterization</a>, with a tool called "the fire drill." The writing says about the disease, "There is no treatment."<a href="#cite_note-8">[8]</a> For centuries, physicians described similar cases in their practises, with the same sad conclusion. It wasn't until doctors achieved greater understanding of the circulatory system in the 17th century that they could establish a link between breast cancer and the <a href="/wiki/index.php?title=Lymph_nodes&action=edit&redlink=1" class="new" title="Lymph nodes (page does not exist)">lymph nodes</a> in the armpit. The French surgeon <a href="/wiki/index.php?title=Jean_Louis_Petit&action=edit&redlink=1" class="new" title="Jean Louis Petit (page does not exist)">Jean Louis Petit</a> (1674-1750) and later the Scottish surgeon <a href="/wiki/index.php?title=Benjamin_Bell&action=edit&redlink=1" class="new" title="Benjamin Bell (page does not exist)">Benjamin Bell</a> (1749-1806) were the first to remove the lymph nodes, breast tissue, and underlying chest muscle. Their successful work was carried on by <a href="/wiki/William_Stewart_Halsted" title="William Stewart Halsted">William Stewart Halsted</a> who started performing <a href="/wiki/index.php?title=Radical_mastectomy&action=edit&redlink=1" class="new" title="Radical mastectomy (page does not exist)">mastectomies</a> in 1882. He became known for his <a href="/wiki/index.php?title=Radical_mastectomy&action=edit&redlink=1" class="new" title="Radical mastectomy (page does not exist)">Halsted radical mastectomy</a>, a surgical procedure that remained popular up to the 1970s. In 1971, the situation changed when a major study revealed no survival improvement of radical mastectomy over lumpectomy with adjuvant radiation.<a href="#cite_note-9">[9]</a> Radical mastectomy, however, reduced quality of life. <h2>Classification</h2> These are the pathological and clinical categories of breast cancer. There can be overlap; for example, a ductal carcinoma can also be an inflammatory breast cancer. <ul><li><a href="/wiki/Ductal_carcinoma" title="Ductal carcinoma">Ductal carcinoma</a> 65-90%</li> <li><a href="/wiki/index.php?title=Lobular_carcinoma&action=edit&redlink=1" class="new" title="Lobular carcinoma (page does not exist)">Lobular carcinoma</a> 10%</li> <li><a href="/wiki/index.php?title=Inflammatory_breast_cancer&action=edit&redlink=1" class="new" title="Inflammatory breast cancer (page does not exist)">Inflammatory breast cancer</a></li> <li><a href="/wiki/index.php?title=Medullary_carcinoma&action=edit&redlink=1" class="new" title="Medullary carcinoma (page does not exist)">Medullary carcinoma</a> 5%</li> <li><a href="/wiki/index.php?title=Colloid_carcinoma&action=edit&redlink=1" class="new" title="Colloid carcinoma (page does not exist)">Colloid carcinoma</a> 2%</li> <li><a href="/wiki/index.php?title=Papillary_carcinoma&action=edit&redlink=1" class="new" title="Papillary carcinoma (page does not exist)">Papillary carcinoma</a> 1%</li> <li><a href="/wiki/index.php?title=Metaplastic_carcinoma&action=edit&redlink=1" class="new" title="Metaplastic carcinoma (page does not exist)">Metaplastic carcinoma</a></li> <li><a href="/wiki/Ductal_carcinoma_in_situ" title="Ductal carcinoma in situ">Ductal carcinoma in situ</a></li></ul> <h2>Pathology</h2> <h3>Metastasis</h3> Most people understand breast cancer as something that happens in the breast. However it can <a href="/wiki/index.php?title=Metastasis&action=edit&redlink=1" class="new" title="Metastasis (page does not exist)">metastasise</a> (spread) via lymphatics to nearby lymph nodes usually those under the arm. That is why surgery for breast cancer always involves some type of surgery for the glands under the arm- either axillary clearance, sampling or sentinel node biopsy. Cancer localized to the breast is rarely fatal. In <a href="/wiki/index.php?title=Metastasis&action=edit&redlink=1" class="new" title="Metastasis (page does not exist)">metastatic breast cancer</a>, the neoplasm in the breast spreads to other parts of the body. So it can spread to the lungs, pleura (the lining of the lungs), the liver, the brain and most commonly to the bones. In fatal outcomes, the tumor has almost always metastasized. Unexplained weight loss can occasionally herald an occult breast cancer, as can symptoms of fevers or chills. Bone or joint pains can sometimes be manifestations of metastatic breast cancer, as can jaundice or neurological symptoms. <a href="/wiki/index.php?title=Pleural_effusions&action=edit&redlink=1" class="new" title="Pleural effusions (page does not exist)">Pleural effusions</a> are not uncommon with <a href="/wiki/index.php?title=Metastatic&action=edit&redlink=1" class="new" title="Metastatic (page does not exist)">metastatic</a> breast cancer. These symptoms are "non-specific," meaning they can also be manifestations of many other illnesses. Seventy percent of the time that breast cancer spreads to other locations, it spreads to bone, especially the vertebrae and the long bones of the arms, legs and ribs. Breast cancer cells "set up house" in the bones and form tumors. When breast cancer is found in bones, it has usually spread to more than one site. At this stage, it is treatable, often for many years, but it is not curable. Specialized <a href="/wiki/Pain_management" title="Pain management">pain management</a> is available for primary or metastatic bone canceer. Usually when breast cancer spreads to bone, it eats away healthy bone causing weak spots. The bones break easily at these weak spots. That is why breast cancer patients are often seen wearing braces or using a wheel chair, and why they complain about aching bones. If a patient had breast cancer in the past and notices pain in the bones, he or she should see a doctor. <h2>Diagnosis</h2> <h3>Symptoms</h3> Breast cancer in an early stage sometimes presents itself as breast pain (<a href="/wiki/index.php?title=Mastodynia&action=edit&redlink=1" class="new" title="Mastodynia (page does not exist)">mastodynia</a>) or a painful lump. Since the advent of breast mammography, breast cancer is most often discovered as an asymptomatic nodule on a mammogram, before any symptoms are present. A lump under the arm or above the <a href="/wiki/index.php?title=Collarbone&action=edit&redlink=1" class="new" title="Collarbone (page does not exist)">collarbone</a> that does not go away may be present. Other possible symptoms or <a href="/wiki/index.php?title=Medical_signs&action=edit&redlink=1" class="new" title="Medical signs (page does not exist)">medical signs</a> include nipple discharge, bleeding from the nipple, new nipple inversion, and changes in the skin overlying the breast which often resembles an orange peel, known as <a href="/wiki/index.php?title=Peau_d%27orange&action=edit&redlink=1" class="new" title="Peau d'orange (page does not exist)">peau d'orange</a> (orange peel skin). Because peau d'orange develops slowly, it is usually a late sign of breast cancer.<a href="#cite_note-10">[10]</a> When breast cancer associates with skin <a href="/wiki/index.php?title=Inflammation&action=edit&redlink=1" class="new" title="Inflammation (page does not exist)">inflammation</a>, this is known as <a href="/wiki/index.php?title=Inflammatory_breast_cancer&action=edit&redlink=1" class="new" title="Inflammatory breast cancer (page does not exist)">inflammatory breast cancer</a>. In inflammatory breast cancer, the breast tumor itself causes an <a href="/wiki/index.php?title=Inflammatory&action=edit&redlink=1" class="new" title="Inflammatory (page does not exist)">inflammatory</a> reaction of the skin, and this can cause pain, swelling, warmth, and redness throughout the entire breast. Changes in the appearance or shape of the breast can raise suspicions of breast cancer.Another reported symptom complex of breast cancer is <a href="/wiki/index.php?title=Paget%27s_disease_of_the_breast&action=edit&redlink=1" class="new" title="Paget's disease of the breast (page does not exist)">Paget's disease of the breast</a>. This <a href="/wiki/Syndrome" title="Syndrome">syndrome</a> presents as <a href="/wiki/index.php?title=Eczematoid&action=edit&redlink=1" class="new" title="Eczematoid (page does not exist)">eczematoid</a> skin changes at the nipple, and is a late manifestation of an underlying breast cancer. Most breast symptoms do not turn out to reflect underlying breast cancer. <a href="/wiki/index.php?title=Benign_breast_diseases&action=edit&redlink=1" class="new" title="Benign breast diseases (page does not exist)">Benign breast diseases</a> such as <a href="/wiki/index.php?title=Fibrocystic_mastopathy&action=edit&redlink=1" class="new" title="Fibrocystic mastopathy (page does not exist)">fibrocystic mastopathy</a>, <a href="/wiki/index.php?title=Mastitis&action=edit&redlink=1" class="new" title="Mastitis (page does not exist)">mastitis</a>, <a href="/wiki/index.php?title=Functional_mastodynia&action=edit&redlink=1" class="new" title="Functional mastodynia (page does not exist)">functional mastodynia</a>, and <a href="/wiki/index.php?title=Fibroadenoma&action=edit&redlink=1" class="new" title="Fibroadenoma (page does not exist)">fibroadenoma</a> of the breast are more common causes of breast symptoms. The appearance of a new breast symptom should be taken seriously by both patients and their doctors, because of the possibility of an underlying breast cancer at almost any age. <h3>Physical examination</h3> The most helpful findings on <a href="/wiki/Physical_examination" title="Physical examination">physical examination</a>, according to a <a href="/wiki/Clinical_prediction_rule" title="Clinical prediction rule">clinical prediction rule</a> are:<a href="#cite_note-pmid21619744-11">[11]</a> <ul><li>age of patient</li> <li>presence of a discrete lump</li> <li>breast lump size 2 cm or more</li> <li>breast thickening</li> <li>lymphadenopathy</li></ul> <h3>Pathological examination</h3> The diagnosis of breast cancer is established by the <a href="/wiki/index.php?title=Pathological&action=edit&redlink=1" class="new" title="Pathological (page does not exist)">pathological</a> (<a href="/wiki/index.php?title=Microscopic&action=edit&redlink=1" class="new" title="Microscopic (page does not exist)">microscopic</a>)examination of surgically removed breast tissue. A number of procedures can obtain tissue or cells prior to definitive treatment for histological or cytological examination. Such procedures include fine-needle aspiration, nipple aspirates, ductal lavage, core needle biopsy, and local surgical excisional <a href="/wiki/index.php?title=Biopsy&action=edit&redlink=1" class="new" title="Biopsy (page does not exist)">biopsy</a>. These diagnostic steps, when coupled with radiographic imaging, are usually accurate in diagnosing a breast lesion as cancer. Occasionally, pre-surgical procedures such as fine needle aspirate may not yield enough tissue to make a diagnosis, or may miss the cancer entirely. Imaging tests are sometimes used to detect <a href="/wiki/index.php?title=Metastasis&action=edit&redlink=1" class="new" title="Metastasis (page does not exist)">metastasis</a> and include <a href="/wiki/Chest_x-ray" class="mw-redirect" title="Chest x-ray">chest x-ray</a>, <a href="/wiki/index.php?title=Bone_scan&action=edit&redlink=1" class="new" title="Bone scan (page does not exist)">bone scan</a>, <a href="/wiki/Cat_scan" class="mw-redirect" title="Cat scan">CT</a>, <a href="/wiki/MRI" class="mw-redirect" title="MRI">MRI</a>, and <a href="/wiki/Positron_emission_tomography" title="Positron emission tomography">PET</a> scanning. While imaging studies are useful in determining the presence of metastatic disease, they are not in and of themselves diagnostic of cancer. Only microscopic evaluation of a biopsy specimen can yield a cancer diagnosis. <a href="/wiki/index.php?title=Ca_15.3&action=edit&redlink=1" class="new" title="Ca 15.3 (page does not exist)">Ca 15.3</a> (carbohydrate antigen 15.3, epithelial mucin) is a <a href="/wiki/index.php?title=Tumor_marker&action=edit&redlink=1" class="new" title="Tumor marker (page does not exist)">tumor marker</a> determined in blood which can be used to follow disease activity over time after definitive treatment. Blood tumor marker testing is not routinely performed for the screening of breast cancer, and has poor performance characteristics for this purpose. <h2>Epidemiologic risk factors and etiology</h2> <a href="/wiki/Epidemiological" class="mw-redirect" title="Epidemiological">Epidemiological</a> risk factors for a disease can provide important clues as to the <a href="/wiki/Etiology" title="Etiology">etiology</a> of a disease. The first work on breast cancer epidemiology was done by <a href="/wiki/index.php?title=Janet_Lane-Claypon&action=edit&redlink=1" class="new" title="Janet Lane-Claypon (page does not exist)">Janet Lane-Claypon</a>, who published a comparative study in 1926 of 500 breast cancer cases and 500 control patients of the same background and lifestyle for the British Ministry of Health. Today, breast cancer, like other forms of cancer, is considered to be the final outcome of multiple environmental and hereditary factors. <ol><li>Lesions to <a href="/wiki/DNA" title="DNA">DNA</a> such as <a href="/wiki/Genetic_mutations" class="mw-redirect" title="Genetic mutations">genetic mutations</a>. Exposure to estrogen has been experimentally linked to the mutations that cause breast cancer.<a href="#cite_note-pmid16675129-12">[12]</a> Beyond the contribution of estrogen, research has implicated <a href="/wiki/index.php?title=Viral_oncogenesis&action=edit&redlink=1" class="new" title="Viral oncogenesis (page does not exist)">viral oncogenesis</a> and the contribution of <a href="/wiki/Ionizing_radiation" title="Ionizing radiation">ionizing radiation</a>.<a href="#cite_note-pmid20368650-13">[13]</a></li> <li>Failure of <a href="/wiki/index.php?title=Immune_surveillance&action=edit&redlink=1" class="new" title="Immune surveillance (page does not exist)">immune surveillance</a>, which usually removes malignancies at early phases of their natural history.</li> <li>Abnormal <a href="/wiki/Growth_factor" title="Growth factor">growth factor</a> signaling in the interaction between <a href="/wiki/index.php?title=Stromal_cells&action=edit&redlink=1" class="new" title="Stromal cells (page does not exist)">stromal cells</a> and <a href="/wiki/index.php?title=Epithelial_cells&action=edit&redlink=1" class="new" title="Epithelial cells (page does not exist)">epithelial cells</a>, for example in the <a href="/wiki/Angiogenesis" title="Angiogenesis">angiogenesis</a> necessary to promote new blood vessel growth near new cancers</li> <li>Inherited defects in <a href="/wiki/index.php?title=DNA_repair_genes&action=edit&redlink=1" class="new" title="DNA repair genes (page does not exist)">DNA repair genes</a>, such as <a href="/wiki/BRCA1_gene" title="BRCA1 gene">BRCA1 gene</a>, <a href="/wiki/BRCA2_gene" title="BRCA2 gene">BRCA2 gene</a> and <a href="/wiki/index.php?title=P53_gene&action=edit&redlink=1" class="new" title="P53 gene (page does not exist)">p53 gene</a>.</li></ol> Although many epidemiological risk factors have been identified, the cause of any individual breast cancer is often unknowable. In other words, epidemiological research informs the patterns of breast cancer incidence across certain populations, but not in a given individual. Approximately 5% of new breast cancers are attributable to hereditary syndromes, while no <a href="/wiki/Etiology" title="Etiology">etiology</a> is known for the other 95% of cases.<a href="#cite_note-Madigan_1995-14">[14]</a> <h3>Age</h3> The risk of getting breast cancer increases with age. A woman who lives to age 90 has a lifetime risk of about 14.3%, or one in seven.<a href="#cite_note-15">[15]</a> The probability of breast cancer rises with age, but breast cancer tends to be more aggressive when it occurs in younger people. One type of breast cancer that is especially aggressive and that occurs disproportionately in younger people is <a href="/wiki/index.php?title=Inflammatory_breast_cancer&action=edit&redlink=1" class="new" title="Inflammatory breast cancer (page does not exist)">inflammatory breast cancer</a>. It is initially <a href="/wiki/index.php?title=Cancer_staging&action=edit&redlink=1" class="new" title="Cancer staging (page does not exist)">staged</a> as Stage IIIb or Stage IV. It also is unique because it often does not present with a lump, so it is often undetected by <a href="/wiki/index.php?title=Mammography&action=edit&redlink=1" class="new" title="Mammography (page does not exist)">mammography</a> or <a href="/wiki/index.php?title=Medical_ultrasonography&action=edit&redlink=1" class="new" title="Medical ultrasonography (page does not exist)">ultrasound</a>. It presents with the signs and symptoms of a breast infection like <a href="/wiki/index.php?title=Mastitis&action=edit&redlink=1" class="new" title="Mastitis (page does not exist)">mastitis</a>, and the treatment is usually a combination of surgery, radiation, and chemotherapy. <h3>Gender</h3> Men have a lower risk of developing breast cancer (approximately 1.08 per 100,000 men per year), but this risk appears to be rising.<a href="#cite_note-Giordano-16">[16]</a> <h3>Heredity</h3> In 5% of breast cancer cases, there is a strong inherited familial risk.<a href="#cite_note-pmid9544766-17">[17]</a> Two autosomal dominant <a href="/wiki/Gene" title="Gene">genes</a>, <a href="/wiki/BRCA1_gene" title="BRCA1 gene">BRCA1 gene</a> and <a href="/wiki/BRCA2_gene" title="BRCA2 gene">BRCA2 gene</a>, account for most of the cases of familial breast cancer. Family members who harbor mutations in these genes have a 60% to 80% risk of developing breast cancer in their lifetimes.<a href="#cite_note-pmid9544766-17">[17]</a> Other associated malignancies include <a href="/wiki/Ovarian_cancer" title="Ovarian cancer">ovarian cancer</a> and <a href="/wiki/Pancreatic_cancer" title="Pancreatic cancer">pancreatic cancer</a>. If a mother or a sister was diagnosed breast cancer, the risk of a hereditary ‘’’<a href="/wiki/BRCA1_gene" title="BRCA1 gene">BRCA1 gene</a>’’’ or ‘’’<a href="/wiki/BRCA2_gene" title="BRCA2 gene">BRCA2 gene</a>’’’ mutation is about 2-fold higher than those women without a familial history. In addition to the BRCA genes associated with breast cancer, the presence of <a href="/wiki/index.php?title=NBR2&action=edit&redlink=1" class="new" title="NBR2 (page does not exist)">NBR2</a>, near breast cancer gene 1, has been discovered, and research into its contribution to breast cancer pathogenesis is ongoing.<a href="#cite_note-BethElton_2007-18">[18]</a> Commercial testing for ‘’’<a href="/wiki/BRCA1_gene" title="BRCA1 gene">BRCA1 gene</a>’’’ and ‘’’<a href="/wiki/BRCA2_gene" title="BRCA2 gene">BRCA2 gene</a>’’’ gene mutations has been available since at least 2004. Genetic testing for BRCA gene mutations is conducted exclusively by <a href="/wiki/index.php?title=Myriad_Genetics&action=edit&redlink=1" class="new" title="Myriad Genetics (page does not exist)">Myriad Genetics</a>, located in <a href="/wiki/index.php?title=Salt_Lake_City&action=edit&redlink=1" class="new" title="Salt Lake City (page does not exist)">Salt Lake City</a>. <h3>Diet</h3> Recent research suggests that low-fat diets may significantly decrease the risk of breast cancer as well as the recurrence of breast cancer.<a href="#cite_note-19">[19]</a> Another study showed no contribution of dietary fat intake on the incidence of breast cancer in over 300,000 women.<a href="#cite_note-pmid8538706-20">[20]</a> A randomized controlled study of the consequences of a low-fat diet, the Women's Health Initiative, failed to demonstrate any reduction in breast cancer incidence with reduction in fat intake.<a href="#cite_note-pmid16467232-21">[21]</a> Another randomized trial, the Nurses' Health Study II, found increased breast cancer incidence in premenopausal women only, with higher intake of animal fat, but not vegetable fat. Taken as a whole, these results point to a possible association between dietary fat intake and breast cancer incidence, though these interactions are hard to measure in large groups of women. An environmental effect is probably responsible for the different rates of breast cancer incidence between countries with different dietary customs. Researchers have long measured that breast cancer rates in an immigrant population soon come to resemble the rates of the host country after a few generations. The reason is speculated to be immigrant uptake of the host country diet. The prototypical example of this phenomenon is the changing rate of breast cancer after the arrival of Japanese immigrants to America. <h3>Alcohol</h3> Alcohol appears to increase the risk of breast cancer, though meaningful increases are limited to higher alcohol intake levels. Among women, breast cancer comprises 60% of alcohol-attributable cancers.<a href="#cite_note-Boffetta_2006-22">[22]</a> The UK's Review of Alcohol: Association with Breast Cancer concludes that "studies confirm previous observations that there appears to be an association between alcohol intake and increased risk of breast cancer in women. On balance, there was a weak association between the amount of alcohol consumed and the relative risk."<a href="#cite_note-UKDOH_Alcohol-23">[23]</a> The National Institute on Alcohol Abuse and Alcoholism (NIAAA) concludes that "Chronic alcohol consumption has been associated with a small (averaging 10 percent) increase in a woman's risk of breast cancer."<a href="#cite_note-Friedenreich_1993-24">[24]</a><a href="#cite_note-Longnecker_1988-25">[25]</a><a href="#cite_note-Longnecker_1992-26">[26]</a><a href="#cite_note-Nasca_1990-27">[27]</a> According to these studies, the risk appears to increase as the quantity and duration of alcohol consumption increases. Other studies, however, have found no evidence of such a link.<a href="#cite_note-Chu_1989-28">[28]</a><a href="#cite_note-Schatzkin_1989-29">[29]</a><a href="#cite_note-Webster_1983-30">[30]</a> The Committee on Carcinogenicity of Chemicals in Food, Consumer Products Non-Technical Summary concludes, "the new research estimates that a woman drinking an average of two units of alcohol per day has a lifetime risk of developing breast cancer 8% higher than a woman who drinks an average of one unit of alcohol per day.<a href="#cite_note-UKDOH_Chemicals-31">[31]</a> The risk of breast cancer further increases with each additional drink consumed per day. The research also concludes that approximately 6% (between 3.2% and 8.8%) of breast cancers reported in the UK each year could be prevented if drinking was reduced to a very low level (i.e. less than 1 unit/week)." Breast cancer incidence seems to increase with increasing alcohol consumption.<a href="#cite_note-pmid11694156-32">[32]</a> It has been reported that "two drinks daily increase the risk of getting breast cancer by about 25 percent" (NCI), but the evidence is inconsistent. The Framingham study has carefully tracked individuals since the 1940s, and found that drinking alcohol moderately did not increase breast cancer risk (Wellness Facts). Similarly, research by the Danish National Institute for Public Health found that moderate drinking had virtually no effect on breast cancer risk.<a href="#cite_note-Petri_2004-33">[33]</a> One study suggests that women who frequently drink red wine may have an increased risk of developing breast cancer.<a href="#cite_note-Maggiolini_2005-34">[34]</a> "Folate intake counteracts breast cancer risk associated with alcohol consumption"<a href="#cite_note-35">[35]</a> and "women who drink alcohol and have a high folate intake are not at increased risk of cancer."<a href="#cite_note-36">[36]</a> Those who have a high (200 micrograms or more per day) level of <a href="/wiki/index.php?title=Folate&action=edit&redlink=1" class="new" title="Folate (page does not exist)">folate</a> (folic acid or Vitamin B9) in their diet are not at increased risk of breast cancer compared to those who abstain from alcohol.<a href="#cite_note-Zhang_1999-37">[37]</a> Foods rich in folate include <a href="/wiki/index.php?title=Citrus_fruit&action=edit&redlink=1" class="new" title="Citrus fruit (page does not exist)">citrus fruits</a>, citrus juices, dark <a href="/wiki/index.php?title=Green_leafy_vegetable&action=edit&redlink=1" class="new" title="Green leafy vegetable (page does not exist)">green leafy vegetables</a> (such as <a href="/wiki/index.php?title=Spinach&action=edit&redlink=1" class="new" title="Spinach (page does not exist)">spinach</a>), dried <a href="/wiki/index.php?title=Bean&action=edit&redlink=1" class="new" title="Bean (page does not exist)">beans</a>, and <a href="/wiki/index.php?title=Pea&action=edit&redlink=1" class="new" title="Pea (page does not exist)">peas</a>. <h3>Obesity</h3> Gaining weight after menopause can increase a woman's risk. A recent study found that putting on 9.9kg (22lbs) after menopause increased the risk of developing breast cancer by 18%.<a href="#cite_note-38">[38]</a> <h3>Radiation</h3> <a href="/wiki/Radiotherapy" title="Radiotherapy">Radiotherapy</a> for childhood cancers may increase the risk of breast cancer.<a href="#cite_note-pmid20368650-13">[13]</a> <h3>Late pregnancy</h3> Giving birth before the age of 24 was shown to be associated with a decreased lifetime risk of contracting breast cancer. Subsequent successful deliveries further increase the protective effect.<a href="#cite_note-Russo2005-39">[39]</a> <h3>Hormones</h3> Persistently increased blood levels of <a href="/wiki/Estrogen" title="Estrogen">estrogen</a> are associated with an increased risk of breast cancer, as are increased levels of the <a href="/wiki/index.php?title=Androgens&action=edit&redlink=1" class="new" title="Androgens (page does not exist)">androgens</a> <a href="/wiki/Androstenedione" title="Androstenedione">androstenedione</a> and <a href="/wiki/Testosterone" title="Testosterone">testosterone</a> (which can be directly converted by <a href="/wiki/Aromatase" title="Aromatase">aromatase</a> to the estrogens <a href="/wiki/index.php?title=Estrone&action=edit&redlink=1" class="new" title="Estrone (page does not exist)">estrone</a> and <a href="/wiki/Estradiol" title="Estradiol">estradiol</a>, respectively). Increased blood levels of <a href="/wiki/Progesterone" title="Progesterone">progesterone</a> are associated with a decreased risk of breast cancer in premenopausal women.<a href="#cite_note-40">[40]</a> A number of circumstances which increase exposure to endogenous estrogens including not having children, delaying first childbirth, not breastfeeding, early <a href="/wiki/index.php?title=Menarche&action=edit&redlink=1" class="new" title="Menarche (page does not exist)">menarche</a> (the first menstrual period) and late <a href="/wiki/Menopause" title="Menopause">menopause</a> are suspected of increasing lifetime risk for developing breast cancer.<a href="#cite_note-41">[41]</a> <a href="/wiki/index.php?title=Hormonal_contraception&action=edit&redlink=1" class="new" title="Hormonal contraception (page does not exist)">Hormonal contraceptives</a> may produce a slight increase in the risk of breast cancer diagnosis among current and recent users, but this appears to be a short-term effect. In 1996 the largest collaborative reanalysis of individual data on over 150,000 women in 54 studies of breast cancer found a <a href="/wiki/Relative_risk" class="mw-redirect" title="Relative risk">relative risk</a> (RR) of 1.24 of breast cancer diagnosis among current <a href="/wiki/index.php?title=Combined_oral_contraceptive_pill&action=edit&redlink=1" class="new" title="Combined oral contraceptive pill (page does not exist)">combined oral contraceptive pill</a> users; 10 or more years after stopping, no difference was seen. Further, the cancers diagnosed in women who had ever used hormonal contraceptives were less advanced than those in nonusers, raising the possibility that the small excess among users was due to increased detection.<a href="#cite_note-oxford_1996a-42">[42]</a><a href="#cite_note-oxford_1996b-43">[43]</a> The relative risk of breast cancer diagnosis associated with current and recent use of hormonal contraceptives did not appear to vary with family history of breast cancer.<a href="#cite_note-hormone-44">[44]</a> Data exist from both observational and <a href="/wiki/index.php?title=Randomized_clinical_trial&action=edit&redlink=1" class="new" title="Randomized clinical trial (page does not exist)">randomized clinical trials</a> regarding the association between postmenopausal <a href="/wiki/index.php?title=Hormone_replacement_therapy&action=edit&redlink=1" class="new" title="Hormone replacement therapy (page does not exist)">hormone replacement therapy</a> (HRT) and breast cancer. The largest meta-analysis (1997) of data from 51 observational studies, indicated a relative risk of breast cancer of 1.35 for women who had used HRT for 5 or more years after menopause. The estrogen-plus-<a href="/wiki/index.php?title=Progestin&action=edit&redlink=1" class="new" title="Progestin (page does not exist)">progestin</a> arm of the <a href="/wiki/Women%27s_Health_Initiative" title="Women's Health Initiative">Women's Health Initiative</a> (WHI), a randomized controlled trial, which randomized more than 16,000 postmenopausal women to receive combined hormone therapy or placebo, was halted early (2002) because health risks exceeded benefits. One of the adverse outcomes prompting closure was a significant increase in both total and invasive breast cancers (RR = 1.24) in women randomized to receive estrogen and progestin for an average of 5 years. HRT-related breast cancers had adverse prognostic characteristics (more advanced stages and larger tumors) compared with cancers occurring in the placebo group, and HRT was also associated with a substantial increase in abnormal mammograms. Short-term use of hormones for treatment of menopausal symptoms appears to confer little or no breast cancer risk.<a href="#cite_note-hormone-44">[44]</a> <h3>Environmental causes</h3> <h4>Tobacco</h4> Most studies have not found an increased risk of breast cancer from active <a href="/wiki/index.php?title=Tobacco_smoking&action=edit&redlink=1" class="new" title="Tobacco smoking (page does not exist)">tobacco smoking</a>, although a number of studies suggest an increased risk of breast cancer in both active smokers and those exposed to <a href="/wiki/index.php?title=Passive_smoking&action=edit&redlink=1" class="new" title="Passive smoking (page does not exist)">secondhand smoke</a> compared to women who reported no exposure to secondhand smoke.<a href="#cite_note-acs_bc_facts_2005-6-45">[45]</a> <h4>Radiation</h4> Women who have received high-dose <a href="/wiki/Ionizing_radiation" title="Ionizing radiation">ionizing radiation</a> to the chest (for example, as treatments for other cancers) have a relative risk of breast cancer between 2.1 to 4.0.<a href="#cite_note-acs_bc_facts_2005-6-45">[45]</a> <h4>Impact of environmental estrogenic mimics</h4> Although environmental exposures are not generally cited as risk factors for the disease (except for diet, pharmaceuticals and radiation), a substantial and growing body of evidence indicates that exposures to certain toxic chemicals and hormone-mimicking compounds including chemicals used in <a href="/wiki/index.php?title=Pesticides&action=edit&redlink=1" class="new" title="Pesticides (page does not exist)">pesticides</a>, <a href="/wiki/index.php?title=Cosmetics&action=edit&redlink=1" class="new" title="Cosmetics (page does not exist)">cosmetics</a> and cleaning products contribute to the development of breast cancer. A recent <a href="/wiki/Canadian" class="mw-redirect" title="Canadian">Canadian</a> study concluded that female farm workers are three times more likely to have breast cancer.<a href="#cite_note-46">[46]</a> The increasing prevalence of these substances in the environment may explain the increasing incidence of breast cancer, though direct evidence is sparse. <h3>Viral breast cancer pathogenesis research</h3> Humans are not the only mammals prone to breast cancer. Some strains of mice, namely the house mouse (Mus domesticus) are prone to breast cancer which is caused by infection with the <a href="/wiki/index.php?title=Mouse_mammary_tumour_virus&action=edit&redlink=1" class="new" title="Mouse mammary tumour virus (page does not exist)">mouse mammary tumour virus</a> (MMTV or "Bittner virus" for its discoverer Hans Bittner), by random insertional mutagenesis. This finding is taken to mean that a viral <a href="/wiki/Etiology" title="Etiology">etiology</a> of human breast cancer is at least possible, though there is no definitive evidence to support the claim that MMTV causes human breast cancer. For example, there may be critical differences between cancer pathogenesis in mice and people. The understanding of the role of MMTV or other viruses in human breast cancer is preliminary as of May 2007. <h3>Factors with minimal impact on breast cancer risk</h3> <h4>Abortion</h4> Studies in rats<a href="#cite_note-RUSSO3-47">[47]</a> led to speculation that <a href="/wiki/index.php?title=Abortion-breast_cancer_hypothesis&action=edit&redlink=1" class="new" title="Abortion-breast cancer hypothesis (page does not exist)">abortion</a> may increase the risk of breast cancer because of hormones initiating breast tissue growth in early pregnancy. Some early interview based <a href="/wiki/index.php?title=Case-control&action=edit&redlink=1" class="new" title="Case-control (page does not exist)">case-control</a> studies indicated a possible correlation,<a href="#cite_note-DALING-48">[48]</a> but more recent large record based studies and <a href="/wiki/Meta-analysis" title="Meta-analysis">meta-analysis</a> studies do not support this association.<a href="#cite_note-MELBYE-49">[49]</a><a href="#cite_note-50">[50]</a> <h4>Deodorants</h4> Much has been made of the possible contribution of aluminium-containing underarm antiperspirants to the incidence of breast cancer, since the most common location of a breast cancer is the upper outer quadrant of the breast. <a href="/wiki/Aluminium" title="Aluminium">Aluminium</a> salts, such as those used in anti-perspirants, have recently been classified as <a href="/wiki/index.php?title=Metalloestrogens&action=edit&redlink=1" class="new" title="Metalloestrogens (page does not exist)">metalloestrogens</a>. Fortunately, this in-vitro association between aluminium salts and estrogen activity does not translate into an increased risk of breast cancer in humans. The lack of association between underarm deodorants and breast cancer has been the subject of a number of research articles.<a href="#cite_note-pmid14991030-51">[51]</a><a href="#cite_note-pmid12543590-52">[52]</a> <h4>Fertility treatments</h4> There is no persuasive connection between fertility medications and breast cancer.<a href="#cite_note-53">[53]</a> <h4>Phytoestrogens and soy</h4> <a href="/wiki/index.php?title=Phytoestrogens&action=edit&redlink=1" class="new" title="Phytoestrogens (page does not exist)">Phytoestrogens</a> such as found in <a href="/wiki/index.php?title=Soybeans&action=edit&redlink=1" class="new" title="Soybeans (page does not exist)">soybeans</a> have been extensively studied in animal and human in-vitro and epidemiological studies. The literature support the following conclusions: <ol><li>Plant estrogen intake, such as from soy products, in early adolescence may protect against breast cancer later in life.<a href="#cite_note-pmid17158751-54">[54]</a></li> <li>Plant estrogen intake later in life is not likely to influence breast cancer incidence either positively or negatively.<a href="#cite_note-55">[55]</a> It seems reasonable to conclude that <a href="/wiki/index.php?title=Soybean&action=edit&redlink=1" class="new" title="Soybean (page does not exist)">soybean</a>-based <a href="/wiki/index.php?title=Phytoestrogens&action=edit&redlink=1" class="new" title="Phytoestrogens (page does not exist)">phytoestrogens</a> are not a major contributor to the incidence of breast cancer.</li></ol> <h2>Prevention in high-risk individuals</h2> <h3>Prophylactic oophorectomy</h3> Prophylactic <a href="/wiki/index.php?title=Oophorectomy&action=edit&redlink=1" class="new" title="Oophorectomy (page does not exist)">oophorectomy</a> (removal of ovaries), in high-risk individuals, when child-bearing is complete, reduces the risk of developing breast cancer by 60%, as well as reducing the risk of developing ovarian cancer by 96%.<a href="#cite_note-Kauff_2002-56">[56]</a> <h3>Managing side effects of prophylactic oophorectomy</h3> <h4>Hormonal treatments</h4> Short-term hormone replacement with estrogen, in high-risk BRCA mutation carriers, was not shown to increase the risk of breast cancer in women who are post-oophorectomy. The results were published in JCO in 2004, and the conclusions based on a computerized simulation using models of risk and benefit, a lower level of data than a randomized trial per se. PMID: 14981106. This result can probably be generalized to other women at high risk, in whom short term (i.e., one or two year) treatment with estrogen for hot flashes, may be acceptable. <h3>Prophylactic mastectomy</h3> Bilateral prophylactic <a href="/wiki/index.php?title=Mastectomy&action=edit&redlink=1" class="new" title="Mastectomy (page does not exist)">mastectomies</a> have been shown to prevent breast cancer in high-risk individuals, such as patients with <a href="/wiki/BRCA1_gene" title="BRCA1 gene">BRCA1 gene</a> or <a href="/wiki/BRCA2_gene" title="BRCA2 gene">BRCA2 gene</a> mutations. <h3>Medications</h3> <a href="/wiki/index.php?title=Hormonal_therapy_(oncology)&action=edit&redlink=1" class="new" title="Hormonal therapy (oncology) (page does not exist)">Hormonal therapy</a> has been used for chemoprevention in individuals at high risk for breast cancer. The current <a rel="nofollow" class="external text" href="https://www.ahrq.gov/clinic/uspstfix.htm">U.S. Preventive Services Task Force (USPSTF)</a> was published in 2009.<a href="#cite_note-pmid19755347-57">[57]</a> Previously, in 2002, a <a href="/wiki/Clinical_practice_guideline" title="Clinical practice guideline">clinical practice guideline</a> by the <a rel="nofollow" class="external text" href="https://www.ahrq.gov/clinic/uspstfix.htm">U.S. Preventive Services Task Force (USPSTF)</a> recommended "clinicians discuss chemoprevention with women at high risk for breast cancer and at low risk for adverse effects of chemoprevention" with a <a rel="nofollow" class="external text" href="https://www.ahrq.gov/clinic/3rduspstf/ratings.htm">grade B recommendation</a>.<a href="#cite_note-pmid12093249-58">[58]</a><a href="#cite_note-pmid12093250-59">[59]</a> <h4>Selective estrogen receptor modulators (SERMs)</h4> The guidelines were based on studies of <a href="/wiki/index.php?title=SERM&action=edit&redlink=1" class="new" title="SERM (page does not exist)">SERMs</a> from the MORE, BCPT P-1, and Italian trials. In the MORE trial, the <a href="/wiki/Relative_risk_reduction" title="Relative risk reduction">relative risk reduction</a> for <a href="/wiki/Raloxifene" title="Raloxifene">raloxifene</a> was 76%.<a href="#cite_note-pmid10376571-60">[60]</a> The P-1 preventative study demonstrated that <a href="/wiki/Tamoxifen" title="Tamoxifen">tamoxifen</a> can prevent breast cancer in high-risk individuals. The <a href="/wiki/Relative_risk_reduction" title="Relative risk reduction">relative risk reduction</a> was up to 50% of new breast cancers, though the cancers prevented were more likely estrogen-receptor positive (this is analogous to the effect of <a href="/wiki/Finasteride" title="Finasteride">finasteride</a> on the prevention of <a href="/wiki/Prostate_cancer" title="Prostate cancer">prostate cancer</a>, in which only low-grade <a href="/wiki/Prostate_cancer" title="Prostate cancer">prostate cancers</a> were prevented).<a href="#cite_note-pmid16288118-61">[61]</a><a href="#cite_note-pmid9747868-62">[62]</a> The Italian trial showed benefit from tamoxifen.<a href="#cite_note-pmid17470740-63">[63]</a> Additional <a href="/wiki/index.php?title=Randomized_controlled_trials&action=edit&redlink=1" class="new" title="Randomized controlled trials (page does not exist)">randomized controlled trials</a> have been published since the guidelines. The IBIS trial found benefit from <a href="/wiki/Tamoxifen" title="Tamoxifen">tamoxifen</a>. <a href="#cite_note-pmid17312304-64">[64]</a>In 2006, the <a href="/wiki/index.php?title=NSABP&action=edit&redlink=1" class="new" title="NSABP (page does not exist)">NSABP</a> STAR trial demonstrated that <a href="/wiki/Raloxifene" title="Raloxifene">raloxifene</a> had equal efficacy in preventing breast cancer compared with <a href="/wiki/Tamoxifen" title="Tamoxifen">tamoxifen</a>, but that there were fewer side effects with <a href="/wiki/Raloxifene" title="Raloxifene">raloxifene</a>.<a href="#cite_note-pmid16754727-65">[65]</a> The RUTH Trial concluded that "benefits of raloxifene in reducing the risks of invasive breast cancer and vertebral fracture should be weighed against the increased risks of venous thromboembolism and fatal stroke".<a href="#cite_note-pmid16837676-66">[66]</a> <a href="/wiki/Raloxifene" title="Raloxifene">Raloxifene</a> is only FDA-approved for <a href="/wiki/Osteoporosis" title="Osteoporosis">osteoporosis</a> as of May 2007. <h2>Screening</h2> <h3>Breast self-examination</h3> Breast self-exam was widely discussed in the 1990s as a useful modality for detecting breast cancer at an earlier stage of presentation. A large clinical trial in China reduced enthusiasm for breast self-exam. In the trial, 132,979 female Chinese factory workers were taught breast self-exam monthly by nurses at their factories, while 133,085 other workers were not taught self-exam. The women taught self-exam tended to detect more breast nodules, but breast cancer mortality was no different from the control women. In other words, women taught breast self-exam were mostly likely to detect benign breast disease, but were just as likely to die of breast cancer. <a href="#cite_note-pmid12359854-67">[67]</a>An editorial in the Journal of the National Cancer Institute reported in 2002, "Routinely Teaching Breast Self-Examination is Dead. What Does This Mean?" <a href="#cite_note-pmid12359843-68">[68]</a> <h3>Clinical breast examination</h3> The Clinical breast examination (a breast examination performed by a trained health care provider), if carefully done over 8 to 10 minutes increases both detection and false positives.<a href="#cite_note-pmid19720967-69">[69]</a> <h3>X-ray mammography</h3> Due to the high incidence of breast cancer among older women, screening is now recommended in many countries. Mammography has been estimated to reduce breast cancer-related mortality by 20-30%.<a href="#cite_note-70">[70]</a> Routine (annual) mammography of women older than forty or fifty years of age is recommended by numerous organizations as a screening method to diagnose early breast cancer, and has demonstrated a protective effect in multiple clinical trials.<a href="#cite_note-71">[71]</a> The evidence in favor of mammographic screening comes from eight randomized clinical trials from the 1960s through 1980s. Many of these trials have been criticised for methodological errors, and the results were summarized in a review article published in 1993.<a href="#cite_note-Fletcher_1993-72">[72]</a> Current summaries of the evidence are provided by the <a href="/wiki/Cochrane_Collaboration" title="Cochrane Collaboration">Cochrane Collaboration</a><a href="#cite_note-pmid21249649-73">[73]</a>, the <a href="/wiki/U.S._Preventive_Services_Task_Force" title="U.S. Preventive Services Task Force">U.S. Preventive Services Task Force</a>, and <a href="/wiki/index.php?title=The_American_College_of_Physicians&action=edit&redlink=1" class="new" title="The American College of Physicians (page does not exist)">the American College of Physicians</a>. In 2009, the <a href="/wiki/U.S._Preventive_Services_Task_Force" title="U.S. Preventive Services Task Force">U.S. Preventive Services Task Force</a> reversed its position on screening mammography for women aged 40-50. This change generated much controversy.<a href="#cite_note-pmid20068215-74">[74]</a> The <a href="/wiki/U.S._Preventive_Services_Task_Force" title="U.S. Preventive Services Task Force">U.S. Preventive Services Task Force</a> most recent <a href="/wiki/Clinical_practice_guideline" title="Clinical practice guideline">clinical practice guidelines</a> were published in 2009:<a href="#cite_note-pmid19920272-75">[75]</a><a href="#cite_note-pmid19920273-76">[76]</a><a href="#cite_note-pmid19920274-4">[4]</a> <ul><li>"The USPSTF recommends biennial screening mammography for women between the ages of 50 and 74 years. (Grade B recommendation)"</li> <li>"The USPSTF concludes that the current evidence is insufficient to assess the additional benefits and harms of screening mammography in women 75 years or older. (I statement)"</li> <li>"The USPSTF concludes that the current evidence is insufficient to assess the additional benefits and harms of clinical breast examination beyond screening mammography in women 40 years or older. (I statement)"</li> <li>"The USPSTF recommends against clinicians teaching women how to perform breast self-examination. (Grade D recommendation)"</li> <li>"The USPSTF concludes that the current evidence is insufficient to assess additional benefits and harms of either digital mammography or magnetic resonance imaging instead of film mammography as screening modalities for breast cancer. (I statement)"</li></ul> The Cochrane concluded: "for every 2000 women invited for screening throughout 10 years, one will have her life prolonged and 10 healthy women, who would not have been diagnosed if there had not been screening, will be treated unnecessarily".<a href="#cite_note-pmid21249649-73">[73]</a> The interval for repeating mammography is not clear.<a href="#cite_note-pmid19920274-4">[4]</a><a href="#cite_note-pmid21916640-77">[77]</a> The appropriate intervals for repeating mammography may range from 2 - 4 years depending on breast density and risk factors.<a href="#cite_note-pmid21727289-78">[78]</a> Reasons for differences of opinion between prior statements of the <a href="/wiki/Cochrane_Collaboration" title="Cochrane Collaboration">Cochrane Collaboration</a> and the <a href="/wiki/U.S._Preventive_Services_Task_Force" title="U.S. Preventive Services Task Force">U.S. Preventive Services Task Force</a> have been reviewed.<a href="#cite_note-pmid12204023-79">[79]</a> Several scientific groups however have expressed concern on the perceived benefits of breast screening by the public.<a href="#cite_note-80">[80]</a> In 2000<a href="#cite_note-pmid10675181-81">[81]</a> and 2001<a href="#cite_note-82">[82]</a>, a controversial <a href="/wiki/Meta-analysis" title="Meta-analysis">meta-analysis</a> by members of the <a href="/wiki/Cochrane_Collaboration" title="Cochrane Collaboration">Cochrane Collaboration</a> claimed that there is no reliable evidence that screening for breast cancer reduces mortality. The final meta-analysis by the Cochrane Collaboration concluded that the <a href="/wiki/Number_needed_to_screen" title="Number needed to screen">number needed to screen</a> is 2000.<a href="#cite_note-pmid17054145-83">[83]</a> <h4>Screening women aged 40 to 50</h4> The <a href="/wiki/U.S._Preventive_Services_Task_Force" title="U.S. Preventive Services Task Force">U.S. Preventive Services Task Force</a> most recent <a href="/wiki/Clinical_practice_guideline" title="Clinical practice guideline">clinical practice guidelines</a> were published in 2009:<a href="#cite_note-pmid19920272-75">[75]</a><a href="#cite_note-pmid19920274-4">[4]</a> <ul><li>"The decision to start regular, biennial screening mammography before the age of 50 years should be an individual one and take patient context into account, including the patient's values regarding specific benefits and harms." This was originally worded as "The USPSTF recommends against routine screening mammography in women aged 40 to 49 years."</li> <li>"The USPSTF concludes that the current evidence is insufficient to assess the additional benefits and harms of clinical breast examination beyond screening mammography in women 40 years or older. (I statement)"</li></ul> However, in 2002, the <a href="/wiki/U.S._Preventive_Services_Task_Force" title="U.S. Preventive Services Task Force">U.S. Preventive Services Task Force</a> promoted mammography in younger women:<a href="#cite_note-pmid12204020-84">[84]</a><a href="#cite_note-pmid12204019-85">[85]</a> <ul><li>"recommends screening mammography, with or without clinical breast examination (CBE), every 1 to 2 years for women aged 40 and older"</li> <li>Regarding women at all ages, the <a href="/wiki/Number_needed_to_screen" title="Number needed to screen">number needed to screen</a> is 1224</li> <li>Regarding women less than 50 years old, the number needed to screen is 1792</li></ul> The American College of Physicians states:<a href="#cite_note-pmid17404353-86">[86]</a><a href="#cite_note-pmid17404354-87">[87]</a> <ol><li>"In women 40 to 49 years of age, clinicians should periodically perform individualized assessment of risk for breast cancer to help guide decisions about screening mammography."</li> <li>"Clinicians should inform women 40 to 49 years of age about the potential benefits and harms of screening mammography"</li> <li>"For women 40 to 49 years of age, clinicians should base screening mammography decisions on benefits and harms of screening, as well as on a woman's preferences and breast cancer risk profile."</li></ol> The U.S. <a href="/wiki/index.php?title=National_Cancer_Institute&action=edit&redlink=1" class="new" title="National Cancer Institute (page does not exist)">National Cancer Institute</a> concludes that the benefit from screening mammography is:<a href="#cite_note-titleBreast_Cancer_Screening_-_National_Cancer_Institute-88">[88]</a> <ul><li>"Absolute mortality benefit for women screened annually starting at age 40 is 4 per 10,000 at 10.7 years." The <a href="/wiki/Number_needed_to_screen" title="Number needed to screen">number needed to screen</a> is 2500.</li> <li>"The comparable number for women screened annually starting at age 50 is approximately 5 per 1000." The number needed to screen is 200.</li></ul> The Institute makes no recommendation about whether screening should be done. The American Cancer Society states:<a href="#cite_note-pmid12809408-89">[89]</a> <ul><li>"Women at average risk should begin annual mammography at age 40."</li></ul> <h4>False positives</h4> False positives are a major problem of mammographic breast cancer screening. Data reported in the UK Million Woman Study indicates that if 134 mammograms are performed, 20 women will be called back for suspicious findings, four biopsies will be necessary, to diagnose one cancer. Recall rates are higher in the USA than in the UK.<a href="#cite_note-pmid15814020-90">[90]</a> The contribution of mammography to the early diagnosis of cancer cannot be overstated, but it comes at a huge financial and psychological cost to the women found to have a nodule. <h4>Overdiagnosis</h4> Mammography may lead to overdiagnosis - detection of true breast cancer that is clinically not relevant.<a href="#cite_note-pmid19589821-91">[91]</a> This may be due to detection of <a href="/wiki/Ductal_carcinoma_in_situ" title="Ductal carcinoma in situ">ductal carcinoma in situ</a> (DCIS).<a href="#cite_note-pmid19920274-4">[4]</a><a href="#cite_note-pmid15070793-92">[92]</a> <h4>Source of controversy</h4> Some of the controversy is due to the variable quality of underlying trials and disagreement over which trials to include in meta-analyses.<a href="#cite_note-pmid12204023-79">[79]</a> <ul><li>The Canadian National Breast Screening Study and Malmö are very well done<a href="#cite_note-pmid12204013-93">[93]</a></li></ul> <h3>Breast MRI</h3> <a href="/wiki/Magnetic_resonance_imaging" title="Magnetic resonance imaging">Magnetic resonance imaging</a> (MRI) has been shown to detect cancers that are not visible on mammograms, but it has several disadvantages. For example, although it is 27-36% more sensitive, it is less specific than mammography.<a href="#cite_note-94">[94]</a> As a result, MRI studies will have more <a href="/wiki/index.php?title=Type_I_and_type_II_errors&action=edit&redlink=1" class="new" title="Type I and type II errors (page does not exist)">false positives</a> (up to 5%), which may have undesirable financial and psychological costs. It is also a relatively expensive procedure, and one which requires the intravenous injection of a chemical agent to be effective. Proposed Indications for using MRI for screening include:<a href="#cite_note-95">[95]</a> <ul><li>Strong family history of breast cancer</li> <li>Patients with <a href="/wiki/BRCA1_gene" title="BRCA1 gene">BRCA1 gene</a> or <a href="/wiki/BRCA2_gene" title="BRCA2 gene">BRCA2 gene</a> mutations</li> <li>Evaluation of women with breast implants</li> <li>History of previous lumpectomy or breast biopsy surgeries</li> <li>Axillary metastasis with an unknown primary tumor</li> <li>Very dense or scarred breast tissue</li></ul> <h3>Breast ultrasound</h3> <a href="/wiki/index.php?title=Medical_ultrasonography&action=edit&redlink=1" class="new" title="Medical ultrasonography (page does not exist)">Ultrasound</a> alone is not usually employed as a screening tool but it is a useful additional tool for the characterization of palpable tumours and directing image-guided biopsies. U-Systems is a US-based company that is selling a breast-cancer detection system using ultrasound that is fully-automated. Using an ultrasound allows a look at dense breast tissue which is not possible with digital mammmography. It is closely correlated with the digital mammography. The other significant advantage over digital mammography is that it is a pain-free procedure. Adding ultrasonography testing for women with dense breast tissue increases the detection of breast cancer, but also increases false positives.<a href="#cite_note-pmid18477782-96">[96]</a><a href="#cite_note-pmid22474203-97">[97]</a> <h3>Genetic testing</h3> Currently, testing for the <a href="/wiki/BRCA1_gene" title="BRCA1 gene">BRCA1 gene</a> and <a href="/wiki/BRCA2_gene" title="BRCA2 gene">BRCA2 gene</a> is may be considered for women whose family history indicates increased risk of breast cancer according to <a href="/wiki/Clinical_practice_guideline" title="Clinical practice guideline">clinical practice guidelines</a> by the <a href="/wiki/U.S._Preventive_Services_Task_Force" title="U.S. Preventive Services Task Force">U.S. Preventive Services Task Force</a>.<a href="#cite_note-pmid16144894-98">[98]</a><a href="#cite_note-99">[99]</a> <h2>Prognosis</h2> <div class="thumb tright"><div class="thumbinner" style="width:352px;"><a href="/wiki/File:5-Year_Relative_Survival_Rates_By_Year_Dx_By_Cancer_Site_All_Ages,_All_Races,_Female_1975-2000.jpg" class="image"><img alt="" src="/wiki/images/thumb/f/fb/5-Year_Relative_Survival_Rates_By_Year_Dx_By_Cancer_Site_All_Ages%2C_All_Races%2C_Female_1975-2000.jpg/350px-5-Year_Relative_Survival_Rates_By_Year_Dx_By_Cancer_Site_All_Ages%2C_All_Races%2C_Female_1975-2000.jpg" decoding="async" width="350" height="472" class="thumbimage" srcset="/wiki/images/thumb/f/fb/5-Year_Relative_Survival_Rates_By_Year_Dx_By_Cancer_Site_All_Ages%2C_All_Races%2C_Female_1975-2000.jpg/525px-5-Year_Relative_Survival_Rates_By_Year_Dx_By_Cancer_Site_All_Ages%2C_All_Races%2C_Female_1975-2000.jpg 1.5x, /wiki/images/f/fb/5-Year_Relative_Survival_Rates_By_Year_Dx_By_Cancer_Site_All_Ages%2C_All_Races%2C_Female_1975-2000.jpg 2x" data-file-width="540" data-file-height="728" /></a> <div class="thumbcaption"><div class="magnify"><a href="/wiki/File:5-Year_Relative_Survival_Rates_By_Year_Dx_By_Cancer_Site_All_Ages,_All_Races,_Female_1975-2000.jpg" class="internal" title="Enlarge"></a></div>5-Year Relative Survival Rates By Year Dx By Cancer Site All Ages, All Races, Female 1975-2000.</div></div></div> There are several prognostic factors associated with breast cancer. <h3>Staging</h3> <a rel="nofollow" class="external text" href="https://www.cancer.gov/cancertopics/pdq/treatment/breast/HealthProfessional/page4">Breast cancer staging</a> information from the <a rel="nofollow" class="external text" href="https://cancer.gov">National Cancer Institute's</a> <a rel="nofollow" class="external text" href="https://www.cancer.gov/cancertopics/pdq">Physician Data Query</a> <a href="/wiki/index.php?title=Cancer_staging&action=edit&redlink=1" class="new" title="Cancer staging (page does not exist)">Stage</a> is the single most important prognostic factor in breast cancer, as it will take into consideration local involvement, lymph node status and whether metastatic disease is present or not. The higher the stage at the time of diagnosis, the worse the prognosis of breast cancer is. Node negative breast cancer patients have a much better prognosis compared to node positive patients. Breast cancer is staged according to the TNM system, updated in the <a rel="nofollow" class="external text" href="http://www.cancerstaging.org/">American Joint Committee on Cancer</a> Staging Manual. Prognosis is closely linked to results of staging, and staging is also used to allocate patients to treatments both in clinical trials and clinical practice. Summary of stages: <ul><li>Stage 0 - <a href="/wiki/index.php?title=Carcinoma_in_situ&action=edit&redlink=1" class="new" title="Carcinoma in situ (page does not exist)">Carcinoma in situ</a></li> <li>Stage I - Tumor (T) does not exceed 2 cm, no axillary lymph nodes (N) involved.</li> <li>Stage IIA – T 2-5 cm, N negative, or T <2 cm and N positive.</li> <li>Stage IIB – T > 5 cm, N negative, or T 2-5 cm and N positive (< 4 axillary nodes).</li> <li>Stage IIIA – T > 5 cm, N positive, or T 2-5 cm with 4 or more axillary nodes</li> <li>Stage IIIB – T has penetrated chest wall or skin, and may have spread to < 10 axillary N</li> <li>Stage IIIC – T has > 10 axillary N, 1 or more supraclavicular or infraclavicular N, or internal mammary N.</li> <li>Stage IV – Distant metastasis (M)</li></ul> <h3>Cell receptor proteins</h3> Breast lesions are examined for certain markers including cytoplasmic receptors for sex steroid hormones and cell surface receptors for epidermal growth factor receptor. <dl><dt>Estrogen receptors</dt></dl> About two thirds of postmenopausal breast cancers are <a href="/wiki/index.php?title=Estrogen_receptor&action=edit&redlink=1" class="new" title="Estrogen receptor (page does not exist)">estrogen receptor</a> positive (ER+) and <a href="/wiki/index.php?title=Progesterone_receptor&action=edit&redlink=1" class="new" title="Progesterone receptor (page does not exist)">progesterone receptor</a> positive (PR+).<a href="#cite_note-100">[100]</a> Hormone receptor positive breast cancer is usually associated with much better prognosis compared to hormone negative breast cancer. Receptor status modifies the treatment as, for instance, only ER-positive tumors, not ER-negative tumors, are sensitive to hormonal therapy. <dl><dt>Epidermal growth factor receptor</dt> <dd>For more information, see: <a href="/wiki/ErbB-2_receptor" title="ErbB-2 receptor">ErbB-2 receptor</a>.</dd></dl> The breast cancer is also usually tested for the presence of <a href="/wiki/ErbB-2_receptor" title="ErbB-2 receptor">ErbB-2 receptor</a>, also called human epidermal growth factor receptor 2, HER2, neu or erbB2. HER2 is a cell-surface protein involved in cell development. In normal cells, HER2 controls aspects of cell growth and division. About 20-30% of breast cancers overexpress HER2. Patients whose cancer cells are positive for HER2/neu have more aggressive disease as when activated in cancer cells, HER2 accelerates tumor formation. Those patients may be candidates for the drug <a href="/wiki/Trastuzumab" title="Trastuzumab">trastuzumab</a> (Herceptin), a <a href="/wiki/Monoclonal_antibody" title="Monoclonal antibody">monoclonal antibody</a> that targets this protein. <a href="/wiki/Trastuzumab" title="Trastuzumab">Trastuzumab</a> may be used both in the postsurgical setting (so-called "<a href="/wiki/index.php?title=Adjuvant&action=edit&redlink=1" class="new" title="Adjuvant (page does not exist)">adjuvant</a>" therapy), and in the metastatic setting.<a href="#cite_note-101">[101]</a> <h3>Gene expression profiling</h3> Recently, the acceleration of <a href="/wiki/index.php?title=Gene_expression_profiling&action=edit&redlink=1" class="new" title="Gene expression profiling (page does not exist)">gene expression profiling</a> research has made available additional markers to predict disease recurrence.<a href="#cite_note-102">[102]</a> Beyond conventional TNM staging, doctors can now order a gene expression profile on tumors to predict whether a breast cancer patient will have a high chance of developing breast cancer again. The test, Oncotype-DX, is not used in every clinical setting; for example, in a patient with positive lymph nodes who is a candidate for chemotherapy, the test would not change therapy decisions. The most useful setting for Oncotype-DX testing is where there are negative lymph nodes, and the benefit of chemotherapy is felt to be small. In up to 10% of patients, there will be disease recurrences, but treating every patient with chemotherapy is overkill. In this setting, a high-risk score on the Oncotype-DX can help doctors decide whether to recommend chemotherapy.<a href="#cite_note-pmid16720680-103">[103]</a> <h2>Treatment</h2> The mainstay of breast cancer treatment is <a href="/wiki/Surgery" title="Surgery">surgery</a> when the tumor is localized, with possible adjuvant hormonal therapy (with <a href="/wiki/Tamoxifen" title="Tamoxifen">tamoxifen</a> or an <a href="/wiki/Aromatase_inhibitor" title="Aromatase inhibitor">aromatase inhibitor</a>), <a href="/wiki/Chemotherapy" class="mw-redirect" title="Chemotherapy">chemotherapy</a>, and/or <a href="/wiki/Radiotherapy" title="Radiotherapy">radiotherapy</a>. At present, the treatment recommendations after surgery (adjuvant therapy) follow a pattern. This pattern is subject to change as every two years a worldwide conference takes place in St. Gallen, Switzerland to discuss the actual results of worldwide multi-center studies. Depending on clinical criteria (age, type of cancer, size, metastasis) patients are roughly divided to high risk and low risk cases which follow different rules for therapy. Treatment possibilities include Radiation Therapy, Chemotherapy, Hormone Therapy, and Immune Therapy. An online resource for helping to quantify the relative risks and benefits of chemotherapy and hormonal therapy is Adjuvant! Online (see below). In planning treatment, doctors can also use PCR tests like <a href="/wiki/index.php?title=Oncotype_DX&action=edit&redlink=1" class="new" title="Oncotype DX (page does not exist)">Oncotype DX</a> or <a href="/wiki/index.php?title=Microarray&action=edit&redlink=1" class="new" title="Microarray (page does not exist)">microarray</a> tests like <a href="/wiki/index.php?title=MammaPrint&action=edit&redlink=1" class="new" title="MammaPrint (page does not exist)">MammaPrint</a> that predict breast cancer recurrence risk based on gene expression. In February 2006, the MammaPrint test became the first breast cancer predictor to win formal approval from the <a href="/wiki/Food_and_Drug_Administration" title="Food and Drug Administration">Food and Drug Administration</a>. This is a new gene test to help predict whether women with early stage breast cancer will relapse in five or 10 years, this could help influence how aggressively they fight the initial tumor.<a href="#cite_note-NewsMax-104">[104]</a> <h3>Surgery</h3> Depending on the staging and type of the tumor, just a <a href="/wiki/index.php?title=Lumpectomy&action=edit&redlink=1" class="new" title="Lumpectomy (page does not exist)">lumpectomy</a> (removal of the lump only) may be all that is necessary or removal of larger amounts of breast tissue may be necessary. Surgical removal of the entire breast is called <a href="/wiki/index.php?title=Mastectomy&action=edit&redlink=1" class="new" title="Mastectomy (page does not exist)">mastectomy</a>. While there has been an increasing utilization of lumpectomy techniques for breast-conservation cancer surgery, mastectomy may be the preferred treatment in certain instances: <ul><li>Two or more tumors exist in different areas of the breast (a "multifocal" cancer).</li> <li>The breast has previously received <a href="/wiki/Radiation" title="Radiation">radiation</a> (XRT) treatment.</li> <li>The tumor is large relative to the size of the breast.</li> <li>The patient has had <a href="/wiki/Scleroderma" class="mw-redirect" title="Scleroderma">scleroderma</a> or another disease of the connective tissue, which can complicate XRT treatment.</li> <li>The patient lives in an area where XRT is inaccessible.</li> <li>The patient is apprehensive about their risk of local recurrence after lumpectomy.</li></ul> Standard practice requires the surgeon to establish that the tissue removed in the operation has margins clear of cancer, indicating that the cancer has been completely excised. If the tissue removed does not have clear margins, then further operations to remove more tissue may be necessary. This may sometimes require removal of part of the <a href="/wiki/index.php?title=Pectoralis_major_muscle&action=edit&redlink=1" class="new" title="Pectoralis major muscle (page does not exist)">pectoralis major muscle</a> which is the main muscle of the anterior chest wall. During the operation, the <a href="/wiki/index.php?title=Lymph_nodes&action=edit&redlink=1" class="new" title="Lymph nodes (page does not exist)">lymph nodes</a> in the <a href="/wiki/index.php?title=Axilla&action=edit&redlink=1" class="new" title="Axilla (page does not exist)">axilla</a> are also considered for removal. In the past, large axillary operations took out ten to forty nodes to establish whether cancer had spread. This had the unfortunate side effect of frequently causing <a href="/wiki/Lymphedema" title="Lymphedema">lymphedema</a> of the arm on the same side, as the removal of this many lymph nodes affected lymphatic drainage. More recently, the technique of <a href="/wiki/index.php?title=Sentinel_lymph_node&action=edit&redlink=1" class="new" title="Sentinel lymph node (page does not exist)">sentinel lymph node</a> (SLN) dissection has become popular, as it requires the removal of far fewer lymph nodes, resulting in fewer side effects. The sentinel lymph node is the first node that drains the tumor, and subsequent SLN mapping can save 65-70% of patients with breast cancer from having a complete lymph node dissection for what could turn out to be a negative nodal basin. Advances in Sentinel Lymph Node mapping over the past decade have increased the accuracy of detecting Sentinel Lymph Node from 80% using blue dye alone to between 92% and 98% using combined modalities.<a href="#cite_note-Bennett_2006-105">[105]</a> SLN biopsy is indicated for patients with T1 and T2 lesions (<5cm) and carries a number of recommendations for use on patient subgroups.<a href="#cite_note-Bennett_2006-105">[105]</a> <h3>Radiation therapy</h3> Radiation therapy consists of the use of high powered X-rays or <a href="/wiki/Gamma_ray" title="Gamma ray">gamma rays</a> (XRT) that precisely target the area that is being treated. These X-rays or gamma rays are very effective in destroying the cancer cells that might recur where the tumor was removed. These X-rays are delivered by a machine called a <a href="/wiki/index.php?title=Linear_particle_accelerator&action=edit&redlink=1" class="new" title="Linear particle accelerator (page does not exist)">linear Accelerator</a> or LINAC. Alternatively, the use of implanted radioactive catheters (brachytherapy), similar to those used in prostate cancer treatment, is being evaluated. The use of radiation therapy for breast cancer is usually given after surgery has been performed and is an essential component of breast conserving therapy. The purpose of radiation is to reduce the chance that the cancer will recur. Radiation therapy works for breast cancer by eliminating the microscopic cancer cells that may remain near the area where the tumor was removed during surgery. Since by the nature of radiation and its effects on normal cells and cancer cells alike the dose that is given is to ensure that the cancer cells are eliminated. However, the dose cannot be given in one sitting. Radiation causes some damage to the normal tissue around where the tumor was but normal healthy tissue can repair itself. The treatments are given typically over a period of five to seven weeks, performed five days a week. Each treatment session takes about fifteen minutes per day. Breaking the treatments up over this extended period of time gives the healthy normal tissue a chance to repair itself. Cancer cells do not repair themselves as well as normal cells, which explains the efficacy of radiation therapy. Although radiation therapy can reduce the chance that breast cancer will recur in the breast, it is much less effective in prolonging patient survival. The National Cancer Institute reviews this information.<a href="#cite_note-106">[106]</a> in a paragraph that begins:“Breast-conserving surgery alone without radiation therapy . . .” The NCI includes six studies; none of them found a survival benefit for radiation therapy. Abstracts from all six studies are available for review. Patients who are unable to have radiation therapy after lumpectomy should consult with a surgeon who understands this research and who believes that lumpectomy (or partial mastectomy) alone is a reasonable treatment option. <h4>Indications for radiation</h4> Indications for radiation treatment are constantly evolving. Patients treated in Europe have been more likely in the past to be recommended adjuvant radiation after breast cancer surgery. <a href="/wiki/Radiation_therapy" class="mw-redirect" title="Radiation therapy">Radiation therapy</a> is usually recommended for all patients who had (lumpectomy, quadrant-resection). Radiation therapy is usually not indicated in patients with advanced (stage IV disease) except for palliation of symptoms like bone pain. In general recommendations would include: <ul><li>As part of breast conserving therapy of breast cancer when the whole breast is not removed (lumpectomy or wide local excision)</li> <li>After mastectomy: Patients with higher chances of cancer recurring such as : large primary tumor and involvement of 4 or more lymph nodes.</li></ul> Other factors which may influence adding adjuvant radiation therapy: <ul><li>Tumor close to or involving the margins on pathology specimen</li> <li>Multiple areas of tumor (multicentric disease)</li> <li>Microscopic invasion of lymphatic or vascular tissues</li> <li>Microcopic invasion of the skin, nipple/areola, or underlying pectoralis major muscle</li> <li>Patients with <4 LN involved, but extension out of the substance of a LN</li> <li>Inadequate numbers of axillary LN sampled</li></ul> <h4>Types of radiotherapy</h4> Radiotherapy can be delivered in many ways. Most commonly this is done using radiation from linear accelerators. Since this is delivered from outside, one needs to restrict the amount of dose that can be given at one time so that normal tissues are not harmed. So the course usually lasts for several days, typically every day for 5 to 6 weeks. New technology has allowed more precise delivery of radiotherapy in a portable fashion - for example in the operating theatre. Targeted intraoperative radiotherapy (TARGIT).<a href="#cite_note-107">[107]</a> is a method of delivering therapeutic radiation from within the breast using a portable x-ray generator called Intrabeam. It is undergoing clinical trials in several countries at present to test whether it can replace the whole course of radiotherapy in selected patients.<a href="#cite_note-Vaidya_2000-108">[108]</a> It may also be able provide a much better boost dose to the tumour bed and appears to provide superior control.<a href="#cite_note-Vaidya_2006-109">[109]</a> This will be tested in a Targit-B trial.<a href="#cite_note-110">[110]</a> <h4>Side effects of radiation therapy</h4> The side effects of radiation have decreased considerably over the past decades. Aside from general fatigue caused by the healthy tissue repairing itself, there will probably be no side effects at all. Some patients develop a suntan-like change in skin color in the exact area being treated. As with a suntan, this darkening of the skin will fade with time. Other side effects experienced with radiation include the fact that radiation therapy can and often does cause permanent changes in the color and texture of skin, in addition to: <ul><li>reddening of the skin</li> <li>muscle stiffness</li> <li>mild swelling</li> <li>tenderness in the area</li> <li>long-term shrinking of the irradiated breast</li></ul> Along with improved cosmetic outcome of treatment with radiation, there have been improvements in the techniques that deliver radiation to the breast. One such new technology is using IMRT (intensity modulated radiation therapy), in which the radiation oncologist can change the shape and intensity of the radiation beam at different points across and inside the breast. This allows for a more focused beam of radiation directed at the tumor cells and leaves most of the healthy tissue unaffected by the radiation. Another new procedure involves a type of <a href="/wiki/Brachytherapy" title="Brachytherapy">brachytherapy</a>, where a radioactive source is temporarily placed inside the breast in direct contact with the tumor bed (area where tumor was removed). This technique is called a Mammosite and is currently undergoing clinic trials. The use of adjuvant radiation has significant potential effects if the patient has to later undergo <a href="/wiki/index.php?title=Breast_reconstruction&action=edit&redlink=1" class="new" title="Breast reconstruction (page does not exist)">breast reconstruction</a> surgery. Fibrosis of chest wall skin from radiation negatively affects skin elasticity and makes <a href="/wiki/index.php?title=Tissue_expansion&action=edit&redlink=1" class="new" title="Tissue expansion (page does not exist)">tissue expansion</a> techniques difficult. Traditionally most patients are advised to defer immediate breast reconstruction when adjuvant radiation is planned and are most often recommended surgery involving autologous tissue reconstruction rather then <a href="/wiki/index.php?title=Breast_implants&action=edit&redlink=1" class="new" title="Breast implants (page does not exist)">breast implants</a>. <h3>Systemic therapy</h3> Systemic therapy uses medications to treat cancer cells throughout the body. Any combination of systemic treatments may be used to treat breast cancer. Systemic treatments include chemotherapy, immune therapy, and hormonal therapy. <h4>Chemotherapy</h4> <a href="/wiki/Chemotherapy" class="mw-redirect" title="Chemotherapy">Chemotherapy</a> (drug treatment for cancer) may used before surgery, after surgery, or instead of surgery in those patients who are unsuitable for surgery. <h5>Nonhormonal</h5> While monoclonal antibodies and other biologicall engineered drugs, simpler molecules continue to have a role in adjuvant treatment and the treatment of metastatic disease. They divide roughly into nonhormonal and hormonal agents. To avoid tumor cell resistance, increase coverage, and decrease side effects, the use of multiple drugs is standard. Greenspan and colleagues first used multiple agents in 1963.<a href="#cite_note-111">[111]</a> By the late sixties, three- to five-drug combinations were common, such as Cooper's regimen of <a href="/wiki/Cyclophosphamide" title="Cyclophosphamide">cyclophosphamide</a>, <a href="/wiki/Methotrexate" title="Methotrexate">methotrexate</a>, 5-fluorouracil, <a href="/wiki/index.php?title=Vincristine&action=edit&redlink=1" class="new" title="Vincristine (page does not exist)">vincristine</a> and <a href="/wiki/Prednisone" title="Prednisone">prednisone</a>. <a href="#cite_note-112">[112]</a> A 1976 review reinforced the importance of using combined, rather than sequential, drugs. <a href="#cite_note-113">[113]</a> The Cooper regimen was high-dose and toxic, although did produce remissions in metastatic disease. In the mid-seventies, low-dose regimens, initially CMF (cyclophosphamide, methotrexate, and 5-fluorouracil) were introduced for adjuvant postoperative chemotherapy, with minimal side effects and improved survival). Modifications were also made to the salvage combined therapies, with the <a href="/wiki/Anthracycline" class="mw-redirect" title="Anthracycline">anthracycline</a> agent, <a href="/wiki/index.php?title=Doxorubricin&action=edit&redlink=1" class="new" title="Doxorubricin (page does not exist)">doxorubricin</a> (Adriamycin) prominent in many.<a href="#cite_note-114">[114]</a> Doxorubricin, however, had a maximum lifetime dose before cardiac toxicity was likely. <h5>Hormonal treatment</h5> Patients with estrogen receptor positive tumors will typically receive a hormonal treatment after chemotherapy is completed. Typical hormonal treatments include: <ul><li><a href="/wiki/Tamoxifen" title="Tamoxifen">Tamoxifen</a> is typically given to premenopausal women to inhibit the estrogen receptors</li> <li><a href="/wiki/Aromatase_inhibitors" class="mw-redirect" title="Aromatase inhibitors">Aromatase inhibitors</a> are typically given to postmenopausal women to lower the amount of estrogen in their systems</li> <li>GnRH-analogues</li> <li>ovarian ablation or suppression is used in premenopausal women</li></ul> In 2007, researchers from Canada's McGill University reported that they have developed a potential drug target for treating up to 40 percent of breast cancers by blocking an <a href="/wiki/Enzyme" title="Enzyme">enzyme</a> called PTPB1, which has been implicated in the onset of breast cancer in mouse models of the disease. Elevated levels of PTPB1 have also been found in <a href="/wiki/Diabetes" class="mw-redirect" title="Diabetes">diabetes</a> and <a href="/wiki/Obesity" title="Obesity">obesity</a>. A drug to block the activity of PTPB1 is under development by <a href="/wiki/index.php?title=Merck_%26_Co.&action=edit&redlink=1" class="new" title="Merck & Co. (page does not exist)">Merck</a>, and was found to delay the development of breast tumors and prevent <a href="/wiki/Lung_cancer" title="Lung cancer">lung cancer</a> up to two months from the administration of the drug. The researchers hope to continue further research in mouse models which are also HER-2 positive (responsive to <a href="/wiki/index.php?title=Herceptin&action=edit&redlink=1" class="new" title="Herceptin (page does not exist)">Herceptin</a>) so that the drug could benefit a significant population of women.<a href="#cite_note-115">[115]</a> <h4>Biologic therapies</h4> <h5>Targeted therapy</h5> In patients whose cancer expresses an over-abundance of the <a href="/wiki/ErbB-2_receptor" title="ErbB-2 receptor">erbB-2 receptor</a> (HER2, HER2/neu), a <a href="/wiki/Monoclonal_antibody" title="Monoclonal antibody">monoclonal antibody</a> known as <a href="/wiki/Trastuzumab" title="Trastuzumab">trastuzumab</a> (Herceptin ®) is used to block the activity of the HER2 protein in breast cancer cells, slowing their growth.<a href="#cite_note-pmid17611206-116">[116]</a> This drug was originally used only in the treatment of patients with metastatic disease, however in the summer of 2005 two large clinical trials published results suggesting that patients with early-stage disease also benefit significantly from trastuzumab.<a href="#cite_note-pmid16236738-117">[117]</a> The drug was approved by the FDA in 1998 for the treatment of metastatic breast cancer, though oncologists have also been using it since 2005 for postoperative patients with localized, Her-2/neu positive disease. <h5>Antiangiogenic therapy</h5> An commercially-available <a href="/wiki/Angiogenesis_inhibitor" title="Angiogenesis inhibitor">angiogenesis inhibitor</a>, a <a href="/wiki/Monoclonal_antibody" title="Monoclonal antibody">monoclonal antibody</a> that blocks the activation of the VEGF receptor, <a href="/wiki/Bevacizumab" title="Bevacizumab">bevacizumab</a>, underwent testing in a <a href="/wiki/index.php?title=Randomized_clinical_trial&action=edit&redlink=1" class="new" title="Randomized clinical trial (page does not exist)">randomized clinical trial</a> in patients with <a href="/wiki/index.php?title=Metastatic&action=edit&redlink=1" class="new" title="Metastatic (page does not exist)">metastatic</a> breast cancer. There has been no formal publication of the data in the peer-reviewed literature as of May, 2007. The data indicate that <a href="/wiki/Bevacizumab" title="Bevacizumab">bevacizumab</a> delays disease progression for up to five months over conventional chemotherapy, but survival was no better. <a href="/wiki/index.php?title=Genentech&action=edit&redlink=1" class="new" title="Genentech (page does not exist)">Genentech</a>, manufacturer of <a href="/wiki/Bevacizumab" title="Bevacizumab">bevacizumab</a>, has filed a supplemental biological application with the <a href="/wiki/Food_and_Drug_Administration" title="Food and Drug Administration">Food and Drug Administration</a> for approval of <a href="/wiki/Bevacizumab" title="Bevacizumab">bevacizumab</a> in the setting of <a href="/wiki/index.php?title=Metastatic&action=edit&redlink=1" class="new" title="Metastatic (page does not exist)">metastatic</a> breast cancer, on the strength of the improvement in <a href="/wiki/index.php?title=Progression-free_survival&action=edit&redlink=1" class="new" title="Progression-free survival (page does not exist)">progression-free survival</a>. It had received accelerated approval based on the <a href="/wiki/index.php?title=Surrogate_marker&action=edit&redlink=1" class="new" title="Surrogate marker (page does not exist)">surrogate marker</a> that it decreased tumor size. On 16 July 2010, the FDA announced "FDA reviewers said two follow-up studies recently submitted by Roche failed to show that Avastin significantly extended lives compared to chemotherapy alone Additionally, the FDA said that in follow-up studies the drug did not slow tumor growth to the same degree as in earlier studies. Patients taking Avastin showed significantly more side effects, including high blood pressure, fatigue and abnormal white blood cell levels." <a href="#cite_note-AP-118">[118]</a> <h2>Follow-up surveillance</h2> Optimal strategies have been <a href="/wiki/Systematic_review" title="Systematic review">systematically reviewed</a><a href="#cite_note-pmid21951942-119">[119]</a><a href="#cite_note-pmid15674884-120">[120]</a><a href="#cite_note-pmid10551200-121">[121]</a> and addressed by <a href="/wiki/Clinical_practice_guideline" title="Clinical practice guideline">clinical practice guidelines</a><a href="#cite_note-pmid23129741-122">[122]</a><a href="#cite_note-pmid10551200-121">[121]</a>. <a href="/wiki/Randomized_controlled_trial" title="Randomized controlled trial">Randomized controlled trials</a> have been conducted.<a href="#cite_note-pmid22474203-97">[97]</a><a href="#cite_note-pmid19119079-123">[123]</a><a href="#cite_note-pmid8182811-124">[124]</a> There is controversy about the best method of follow-up.<a href="#cite_note-pmid24627271-125">[125]</a><a href="#cite_note-pmid24726438-126">[126]</a><a href="#cite_note-pmid25329669-127">[127]</a> <h2>Breast cancer in males</h2> Less than 1% of breast cancers occur in men, and incidence is about 1 in 100,000. Men with <a href="/wiki/index.php?title=Gynaecomastia&action=edit&redlink=1" class="new" title="Gynaecomastia (page does not exist)">gynaecomastia</a> do not have a higher risk of developing breast cancer.<a href="#cite_note-128">[128]</a> There may be an increased incidence of breast cancer in men with <a href="/wiki/Prostate_cancer" title="Prostate cancer">prostate cancer</a>. The prognosis, even in stage I cases, is worse in men than in women.<a href="#cite_note-AMN-129">[129]</a> The treatment of men with breast cancer is similar to that in older women. Since the male breast tissue is confined to the area directly behind the nipple, treatment for males has usually been a <a href="/wiki/index.php?title=Mastectomy&action=edit&redlink=1" class="new" title="Mastectomy (page does not exist)">mastectomy</a> with axillary surgery. This may be followed by adjuvant radiotherapy, hormone therapy (such as tamoxifen), or chemotherapy. <h2>Psychological aspects of breast cancer diagnosis and treatment</h2> The emotional impact of cancer diagnosis, symptoms, treatment, and related issues can be severe. Most larger hospitals are associated with <a href="/wiki/index.php?title=Cancer_support_group&action=edit&redlink=1" class="new" title="Cancer support group (page does not exist)">cancer support groups</a> which can help patients cope with the many issues that come up in a supportive environment with other people with experience with similar issues. Online <a href="/wiki/index.php?title=Cancer_support_group&action=edit&redlink=1" class="new" title="Cancer support group (page does not exist)">cancer support groups</a> are also very beneficial to cancer patients, especially in dealing with uncertainty and body-image problems inherent in cancer treatment. <h2>Attribution</h2> <dl><dd>Some content on this page may previously have <a rel="nofollow" class="external text" href="https://en.wikipedia.org/wiki?title=Breast+cancer">appeared on Wikipedia</a>.</dd></dl> <h2>References</h2> <div class="references" style="-moz-column-count:2; column-count:2;"><div class="mw-references-wrap mw-references-columns"><ol class="references"> <li id="cite_note-who_fact_sheet-1">↑ <a href="#cite_ref-who_fact_sheet_1-0">1.0</a> <a href="#cite_ref-who_fact_sheet_1-1">1.1</a> <a href="/wiki/World_Health_Organization" title="World Health Organization">WHO</a> (February 2006). <a rel="nofollow" class="external text" href="http://www.who.int/mediacentre/factsheets/fs297/en/index.html">Fact sheet No. 297: Cancer</a>. Retrieved on 2007-04-26. </li> <li id="cite_note-acs_cancer_facts_2007-2"><a href="#cite_ref-acs_cancer_facts_2007_2-0">↑</a> American Cancer Society (2007). <a rel="nofollow" class="external text" href="http://www.cancer.org/downloads/STT/CAFF2007PWSecured.pdf">Cancer Facts & Figures 2007</a>. Retrieved on 2007-04-26. </li> <li id="cite_note-acs_bc_key_stats-3">↑ <a href="#cite_ref-acs_bc_key_stats_3-0">3.0</a> <a href="#cite_ref-acs_bc_key_stats_3-1">3.1</a> American Cancer Society (2006-09-18). <a rel="nofollow" class="external text" href="http://www.cancer.org/docroot/CRI/content/CRI_2_4_1X_What_are_the_key_statistics_for_breast_cancer_5.asp">What Are the Key Statistics for Breast Cancer?</a>. Retrieved on 2007-05-22. </li> <li id="cite_note-pmid19920274-4">↑ <a href="#cite_ref-pmid19920274_4-0">4.0</a> <a href="#cite_ref-pmid19920274_4-1">4.1</a> <a href="#cite_ref-pmid19920274_4-2">4.2</a> <a href="#cite_ref-pmid19920274_4-3">4.3</a> <a href="#cite_ref-pmid19920274_4-4">4.4</a> <cite style="font-style:normal">Mandelblatt JS, Cronin KA, Bailey S, Berry DA, de Koning HJ, Draisma G et al. (2009). <a rel="nofollow" class="external text" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=19920274">"Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms."</a>. Ann Intern Med 151 (10): 738-47. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">DOI</a>:<a rel="nofollow" class="external text" href="https://dx.doi.org/10.1059/0003-4819-151-10-200911170-00010">10.1059/0003-4819-151-10-200911170-00010</a>. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/19920274?dopt=Abstract">PMID 19920274</a>. <a rel="nofollow" class="external text" href="http://researchblogging.org/post-search/list?search_text=10.1059/0003-4819-151-10-200911170-00010">Research Blogging</a>.</cite> </li> <li id="cite_note-indy-5"><a href="#cite_ref-indy_5-0">↑</a> Laurance, Jeremy. <a rel="nofollow" class="external text" href="http://news.independent.co.uk/uk/health_medical/article1771835.ece">Breast cancer cases rise 80% since Seventies</a>, <a href="/wiki/index.php?title=The_Independent&action=edit&redlink=1" class="new" title="The Independent (page does not exist)">The Independent</a>, 2006-09-29. Retrieved on 2006-10-09. </li> <li id="cite_note-6"><a href="#cite_ref-6">↑</a> <a rel="nofollow" class="external text" href="http://imaginis.com/breasthealth/statistics.asp">Breast Cancer: Statistics on Incidence, Survival, and Screening</a>. <a rel="nofollow" class="external text" href="http://imaginis.com">Imaginis Corporation</a> (2006). Retrieved on 2006-10-09. </li> <li id="cite_note-Dave-7"><a href="#cite_ref-Dave_7-0">↑</a> <a rel="nofollow" class="external text" href="https://www.cancer.gov/cancertopics/pdq/treatment/malebreast/healthprofessional">Male Breast Cancer Treatment - National Cancer Institute</a>. <a rel="nofollow" class="external text" href="https://www.cancer.gov/">National Cancer Institute</a> (2006). Retrieved on 2006-10-16. </li> <li id="cite_note-8"><a href="#cite_ref-8">↑</a> <a rel="nofollow" class="external text" href="http://www.cancer.org/docroot/CRI/content/CRI_2_6x_the_history_of_cancer_72.asp?sitearea=CRI">The History of Cancer</a>. <a href="/wiki/American_Cancer_Society" title="American Cancer Society">American Cancer Society</a> (2002-03-25). Retrieved on 2006-10-09. </li> <li id="cite_note-9"><a href="#cite_ref-9">↑</a> Fisher B, Bauer M, Margolese R, et al. Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. N Engl J Med. Mar 14 1985;312(11):665-73. </li> <li id="cite_note-10"><a href="#cite_ref-10">↑</a> <a rel="nofollow" class="external free" href="http://www.wrongdiagnosis.com/b/breast_cancer/book-diseases-16c.htm">http://www.wrongdiagnosis.com/b/breast_cancer/book-diseases-16c.htm</a> </li> <li id="cite_note-pmid21619744-11"><a href="#cite_ref-pmid21619744_11-0">↑</a> <cite style="font-style:normal">McCowan C, Donnan PT, Dewar J, Thompson A, Fahey T (2011). "Identifying suspected breast cancer: development and validation of a clinical prediction rule.". Br J Gen Pract 61 (586): 205-14. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">DOI</a>:<a rel="nofollow" class="external text" href="https://dx.doi.org/10.3399/bjgp11X572391">10.3399/bjgp11X572391</a>. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/21619744?dopt=Abstract">PMID 21619744</a>. PMC <a rel="nofollow" class="external text" href="http://www.pubmedcentral.nih.gov/articlerender.fcgi?pubmedid=21619744">PMC3080225</a>. <a rel="nofollow" class="external text" href="http://researchblogging.org/post-search/list?search_text=10.3399/bjgp11X572391">Research Blogging</a>.</cite> </li> <li id="cite_note-pmid16675129-12"><a href="#cite_ref-pmid16675129_12-0">↑</a> <cite style="font-style:normal">Cavalieri E, Chakravarti D, Guttenplan J, et al (2006). "Catechol estrogen quinones as initiators of breast and other human cancers: implications for biomarkers of susceptibility and cancer prevention". Biochim. Biophys. Acta 1766 (1): 63-78. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">DOI</a>:<a rel="nofollow" class="external text" href="https://dx.doi.org/10.1016/j.bbcan.2006.03.001">10.1016/j.bbcan.2006.03.001</a>. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/16675129?dopt=Abstract">PMID 16675129</a>. <a rel="nofollow" class="external text" href="http://researchblogging.org/post-search/list?search_text=10.1016/j.bbcan.2006.03.001">Research Blogging</a>.</cite> </li> <li id="cite_note-pmid20368650-13">↑ <a href="#cite_ref-pmid20368650_13-0">13.0</a> <a href="#cite_ref-pmid20368650_13-1">13.1</a> <cite style="font-style:normal">Henderson TO, Amsterdam A, Bhatia S, Hudson MM, Meadows AT, Neglia JP et al. (2010). <a rel="nofollow" class="external text" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=20368650">"Systematic review: surveillance for breast cancer in women treated with chest radiation for childhood, adolescent, or young adult cancer."</a>. Ann Intern Med 152 (7): 444-55; W144-54. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">DOI</a>:<a rel="nofollow" class="external text" href="https://dx.doi.org/10.1059/0003-4819-152-7-201004060-00009">10.1059/0003-4819-152-7-201004060-00009</a>. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/20368650?dopt=Abstract">PMID 20368650</a>. <a rel="nofollow" class="external text" href="http://researchblogging.org/post-search/list?search_text=10.1059/0003-4819-152-7-201004060-00009">Research Blogging</a>.</cite> </li> <li id="cite_note-Madigan_1995-14"><a href="#cite_ref-Madigan_1995_14-0">↑</a> <cite style="font-style:normal">Madigan MP et al. (1995). "Proportion of breast cancer cases in the United States explained by well-established risk factors". J Natl Cancer Inst 87: 1681-5. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/7473816?dopt=Abstract">PMID 7473816</a>. Retrieved on 2007-05-26. [<a rel="nofollow" class="external text" href="http://en.citizendium.org/wiki?title=CZ:Ref:DOI:&action=edit">e</a>]</cite> </li> <li id="cite_note-15"><a href="#cite_ref-15">↑</a> <a rel="nofollow" class="external text" href="http://www.breastcancer.org/cmn_who_indrisk.html">Individual Risk Factors</a>. BreastCander.org. Retrieved on 2007-03-11. </li> <li id="cite_note-Giordano-16"><a href="#cite_ref-Giordano_16-0">↑</a> <cite style="font-style:normal">Giordano, SH (2004). <a rel="nofollow" class="external text" href="http://www3.interscience.wiley.com/cgi-bin/fulltext/108565241/HTMLSTART">"Breast carcinoma in men"</a>. Cancer 101: 51-7. [<a rel="nofollow" class="external text" href="http://en.citizendium.org/wiki?title=CZ:Ref:DOI:&action=edit">e</a>]</cite> </li> <li id="cite_note-pmid9544766-17">↑ <a href="#cite_ref-pmid9544766_17-0">17.0</a> <a href="#cite_ref-pmid9544766_17-1">17.1</a> <cite style="font-style:normal">Malone KE et al. (1998). "BRCA1 mutations and breast cancer in the general population: analyses in women before age 35 years and in women before age 45 years with first-degree family history". JAMA 279: 922-9. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/9544766?dopt=Abstract">PMID 9544766</a>. [<a rel="nofollow" class="external text" href="http://en.citizendium.org/wiki?title=CZ:Ref:DOI:&action=edit">e</a>]</cite> </li> <li id="cite_note-BethElton_2007-18"><a href="#cite_ref-BethElton_2007_18-0">↑</a> <cite style="font-style:normal">Auriol E et al. (2005). "Specific binding of the methyl binding domain protein 2 at the BRCA1-NBR2 locus". Nucleic Acids Research 33: 4243-54.</cite> </li> <li id="cite_note-19"><a href="#cite_ref-19">↑</a> <cite style="font-style:normal">Chlebowski RT et al.. "Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study (WINS).". J Natl Cancer Inst 98: 1767-76. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/17179478?dopt=Abstract">PMID 17179478</a>.</cite> </li> <li id="cite_note-pmid8538706-20"><a href="#cite_ref-pmid8538706_20-0">↑</a> <cite style="font-style:normal">Hunter DJ et al. (1996). "Cohort studies of fat intake and the risk of breast cancer--a pooled analysis". N Engl J Med 334: 356-61. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/8538706?dopt=Abstract">PMID 8538706</a>. [<a rel="nofollow" class="external text" href="http://en.citizendium.org/wiki?title=CZ:Ref:DOI:&action=edit">e</a>]</cite> </li> <li id="cite_note-pmid16467232-21"><a href="#cite_ref-pmid16467232_21-0">↑</a> <cite style="font-style:normal">Prentice RL et al. (2006). "Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial". JAMA 295: 629-42. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">DOI</a>:<a rel="nofollow" class="external text" href="https://dx.doi.org/10.1001/jama.295.6.629">10.1001/jama.295.6.629</a>. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/16467232?dopt=Abstract">PMID 16467232</a>. <a rel="nofollow" class="external text" href="http://researchblogging.org/post-search/list?search_text=10.1001/jama.295.6.629">Research Blogging</a>.</cite> </li> <li id="cite_note-Boffetta_2006-22"><a href="#cite_ref-Boffetta_2006_22-0">↑</a> <cite style="font-style:normal">Boffetta, P; et al. (2006-03-23). <a rel="nofollow" class="external text" href="http://www3.interscience.wiley.com/cgi-bin/abstract/112550783/ABSTRACT">"The burden of cancer attributable to alcohol drinking"</a>. Int J Cancer 119: 884–7. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">DOI</a>:<a rel="nofollow" class="external text" href="https://dx.doi.org/10.1002/ijc.21903">10.1002/ijc.21903</a>. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/16557583?dopt=Abstract">PMID 16557583</a>. Retrieved on 2006-10-09. <a rel="nofollow" class="external text" href="http://researchblogging.org/post-search/list?search_text=10.1002/ijc.21903">Research Blogging</a>.</cite> </li> <li id="cite_note-UKDOH_Alcohol-23"><a href="#cite_ref-UKDOH_Alcohol_23-0">↑</a> <a rel="nofollow" class="external text" href="http://www.advisorybodies.doh.gov.uk/pdfs/alcbrrev.pdf">Review of Alcohol: Association with Breast Cancer</a>. U.K. Dept. of Health. Retrieved on 2007-03-11. </li> <li id="cite_note-Friedenreich_1993-24"><a href="#cite_ref-Friedenreich_1993_24-0">↑</a> <cite style="font-style:normal">Friedenreich C et al. (1993). "A cohort study of alcohol consumption and risk of breast cancer". Am J Epidemiol 137: 512-20. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/8465803?dopt=Abstract">PMID 8465803</a>.</cite> </li> <li id="cite_note-Longnecker_1988-25"><a href="#cite_ref-Longnecker_1988_25-0">↑</a> <cite style="font-style:normal">Longnecker M et al. (1988). "A meta-analysis of alcohol consumption in relation to risk of breast cancer". JAMA 260: 652-6. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/3392790?dopt=Abstract">PMID 3392790</a>.</cite> </li> <li id="cite_note-Longnecker_1992-26"><a href="#cite_ref-Longnecker_1992_26-0">↑</a> <cite style="font-style:normal">Longnecker MP (1992). "Alcohol consumption in relation to risk of cancers of the breast and large bowel". Alcohol Health & Research World 16: 223-9.</cite> </li> <li id="cite_note-Nasca_1990-27"><a href="#cite_ref-Nasca_1990_27-0">↑</a> <cite style="font-style:normal">Nasca P et al. (1990). "An epidemiological case-control study of breast cancer and alcohol consumption". Int J Epidemiol 19: 532-8. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/2262245?dopt=Abstract">PMID 2262245</a>.</cite> </li> <li id="cite_note-Chu_1989-28"><a href="#cite_ref-Chu_1989_28-0">↑</a> <cite style="font-style:normal">Chu S et al. (1989). "Alcohol consumption and the risk of breast cancer". Am J Epidemiol 130: 867-77. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/2683749?dopt=Abstract">PMID 2683749</a>.</cite> </li> <li id="cite_note-Schatzkin_1989-29"><a href="#cite_ref-Schatzkin_1989_29-0">↑</a> <cite style="font-style:normal">Schatzkin A et al, (1989). "Alcohol consumption and breast cancer: a cross-national correlation study". Int J Epidemiol 18: 28-31. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/2722377?dopt=Abstract">PMID 2722377</a>.</cite> </li> <li id="cite_note-Webster_1983-30"><a href="#cite_ref-Webster_1983_30-0">↑</a> <cite style="font-style:normal">Webster L et al. (1983). "Alcohol consumption and risk of breast cancer". Lancet 2: 724-6. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/6136850?dopt=Abstract">PMID 6136850</a>.</cite> </li> <li id="cite_note-UKDOH_Chemicals-31"><a href="#cite_ref-UKDOH_Chemicals_31-0">↑</a> <a rel="nofollow" class="external text" href="http://www.advisorybodies.doh.gov.uk/pdfs/alco04nontech.pdf">CONSUMPTION OF ALCOHOLIC BEVERAGES AND RISK OF BREAST CANCER IN WOMEN</a>. U.K. Dept. of Health. Retrieved on 2007-03-11. </li> <li id="cite_note-pmid11694156-32"><a href="#cite_ref-pmid11694156_32-0">↑</a> <cite style="font-style:normal">Singletary KW, Gapstur SM (2001). "Alcohol and breast cancer: review of epidemiologic and experimental evidence and potential mechanisms". JAMA 286: 2143-51. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/11694156?dopt=Abstract">PMID 11694156</a>. [<a rel="nofollow" class="external text" href="http://en.citizendium.org/wiki?title=CZ:Ref:DOI:&action=edit">e</a>]</cite> </li> <li id="cite_note-Petri_2004-33"><a href="#cite_ref-Petri_2004_33-0">↑</a> <cite style="font-style:normal">Petri A, et al. (2004). "Alcohol intake, type of beverage, and risk of breast cancer in pre- and postmenopausal women". Alcohol Clin Exp Res 28: 1084-90. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/15252295?dopt=Abstract">PMID 15252295</a>.</cite> </li> <li id="cite_note-Maggiolini_2005-34"><a href="#cite_ref-Maggiolini_2005_34-0">↑</a> <cite style="font-style:normal">Maggiolini M et al. (2005). "The red wine phenolics piceatannol and myricetin act as agonists for estrogen receptor alpha in human breast cancer cells". J Mol Endocrinol 35: 269-81. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/16216908?dopt=Abstract">PMID 16216908</a>.</cite> </li> <li id="cite_note-35"><a href="#cite_ref-35">↑</a> Mayo Clinic news release <a href="/wiki/index.php?title=June_26&action=edit&redlink=1" class="new" title="June 26 (page does not exist)">June 26</a> 2001 <a rel="nofollow" class="external text" href="http://www.mayoclinic.org/news2001-rst/857.html">"Folate Intake Counteracts Breast Cancer Risk Associated with Alcohol Consumption"</a> </li> <li id="cite_note-36"><a href="#cite_ref-36">↑</a> Boston University <a rel="nofollow" class="external text" href="http://www.bu.edu/act/alcoholandhealth/issues/issue_may04/html/04-0506-ellison_baily.html">Folate, Alcohol, and Cancer Risk</a> </li> <li id="cite_note-Zhang_1999-37"><a href="#cite_ref-Zhang_1999_37-0">↑</a> <cite style="font-style:normal">Zhang S et al. (1999). "A prospective study of folate intake and the risk of breast cancer". JAMA 281: 1632-7. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/10235158?dopt=Abstract">PMID 10235158</a>.</cite> </li> <li id="cite_note-38"><a href="#cite_ref-38">↑</a> BBC report <a rel="nofollow" class="external text" href="http://news.bbc.co.uk/1/hi/health/5171838.stm">Weight link to breast cancer risk</a> </li> <li id="cite_note-Russo2005-39"><a href="#cite_ref-Russo2005_39-0">↑</a> <cite style="font-style:normal" class="external text" id="CITEREFRusso,_J._''et_al.''2005">Russo, J. et al. (2005), "<a rel="nofollow" class="external text" href="http://breast-cancer-research.com/content/7/3/131">The protective role of pregnancy in breast cancer</a>", Breast Cancer Res 7: 131–42, <a href="/wiki/Digital_object_identifier" title="Digital object identifier">DOI</a>:<a rel="nofollow" class="external text" href="https://dx.doi.org/10.1186/bcr1029">10.1186/bcr1029</a></cite> </li> <li id="cite_note-40"><a href="#cite_ref-40">↑</a> <cite style="font-style:normal">Yager JD; Davidson NE (2006). "Estrogen carcinogenesis in breast cancer". New Engl J Med 354: 270-82. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/16421368?dopt=Abstract">PMID 16421368</a>.</cite> </li> <li id="cite_note-41"><a href="#cite_ref-41">↑</a> American Cancer Society. (<a href="/wiki/index.php?title=2006-10-03&action=edit&redlink=1" class="new" title="2006-10-03 (page does not exist)">2006-10-03</a>). <a rel="nofollow" class="external text" href="http://www.cancer.org/docroot/CRI/content/CRI_2_4_2X_What_are_the_risk_factors_for_breast_cancer_5.asp">What Are the Risk Factors for Breast Cancer?</a>. </li> <li id="cite_note-oxford_1996a-42"><a href="#cite_ref-oxford_1996a_42-0">↑</a> <cite style="font-style:normal">Collaborative Group on Hormonal Factors in Breast Cancer (1996). "Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies". Lancet 347: 1713-27. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/8656904?dopt=Abstract">PMID 8656904</a>.</cite> </li> <li id="cite_note-oxford_1996b-43"><a href="#cite_ref-oxford_1996b_43-0">↑</a> <cite style="font-style:normal">Collaborative Group on Hormonal Factors in Breast Cancer (1996). "Breast cancer and hormonal contraceptives: further results". Contraception 54 Suppl: 1S-106S. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/8899264?dopt=Abstract">PMID 8899264</a>.</cite> </li> <li id="cite_note-hormone-44">↑ <a href="#cite_ref-hormone_44-0">44.0</a> <a href="#cite_ref-hormone_44-1">44.1</a> National Cancer Institute (2006-08-03). <a rel="nofollow" class="external text" href="https://www.cancer.gov/cancertopics/pdq/genetics/breast-and-ovarian/healthprofessional#Section_340">Hormone Therapy</a>. Genetics of Breast and Ovarian Cancer. Retrieved on 2006-08-12. </li> <li id="cite_note-acs_bc_facts_2005-6-45">↑ <a href="#cite_ref-acs_bc_facts_2005-6_45-0">45.0</a> <a href="#cite_ref-acs_bc_facts_2005-6_45-1">45.1</a> <a href="/wiki/American_Cancer_Society" title="American Cancer Society">ACS</a> (2005). <a rel="nofollow" class="external text" href="http://www.cancer.org/downloads/STT/CAFF2005BrFacspdf2005.pdf">Breast Cancer Facts & Figures 2005-2006</a>. Retrieved on 2007-04-26. </li> <li id="cite_note-46"><a href="#cite_ref-46">↑</a> Ctv.Ca News Staff. <a rel="nofollow" class="external text" href="http://www.ctv.ca/servlet/ArticleNews/story/CTVNews/20061012/breastcancer_farming_061012/20061012?hub=Health">Breast cancer more likely in farm workers: study</a>, Ctv.Ca, 2006-10-12. Retrieved on 2007-03-11. </li> <li id="cite_note-RUSSO3-47"><a href="#cite_ref-RUSSO3_47-0">↑</a> <cite style="font-style:normal">Russo J, Russo I (1987). "Biological and molecular bases of mammary carcinogenesis". Lab Invest 57: 112-37. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/3302534?dopt=Abstract">PMID 3302534</a>.</cite> </li> <li id="cite_note-DALING-48"><a href="#cite_ref-DALING_48-0">↑</a> Daling J.R. et al. (1994) <a rel="nofollow" class="external text" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=7932822">PubMed</a> (1994) Risk of breast cancer among young women: relationship to induced abortion. J Natl Cancer Inst 86:1584-92 </li> <li id="cite_note-MELBYE-49"><a href="#cite_ref-MELBYE_49-0">↑</a> <cite style="font-style:normal">Melbye M et al. (1997). "Induced abortion and the risk of breast cancer". N Engl J Med 336 (2): 81-5. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/8988884?dopt=Abstract">PMID 8988884</a>.</cite> </li> <li id="cite_note-50"><a href="#cite_ref-50">↑</a> Beral V et al.(2004) Breast cancer and abortion: collaborative reanalysis of data from 53 epidemiological studies, including 83,000 women with breast cancer from 16 countries. Lancet 363:1007-16 <a rel="nofollow" class="external text" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?itool=abstractplus&db=pubmed&cmd=Retrieve&dopt=abstractplus&list_uids=15051280">PMID 15051280</a> </li> <li id="cite_note-pmid14991030-51"><a href="#cite_ref-pmid14991030_51-0">↑</a> <cite style="font-style:normal">Surendran A (2004). "Studies linking breast cancer to deodorants smell rotten, experts say". Nat. Med. 10: 216. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">DOI</a>:<a rel="nofollow" class="external text" href="https://dx.doi.org/10.1038/nm0304-216b">10.1038/nm0304-216b</a>. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/14991030?dopt=Abstract">PMID 14991030</a>. <a rel="nofollow" class="external text" href="http://researchblogging.org/post-search/list?search_text=10.1038/nm0304-216b">Research Blogging</a>.</cite> </li> <li id="cite_note-pmid12543590-52"><a href="#cite_ref-pmid12543590_52-0">↑</a> <cite style="font-style:normal"> (2003) "Antiperspirants don't cause breast cancer". Harvard women's health watch 10: 7. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/12543590?dopt=Abstract">PMID 12543590</a>. [<a rel="nofollow" class="external text" href="http://en.citizendium.org/wiki?title=CZ:Ref:DOI:&action=edit">e</a>]</cite> </li> <li id="cite_note-53"><a href="#cite_ref-53">↑</a> <cite style="font-style:normal">Potashnik G et al. (1999). "Fertility drugs and the risk of breast and ovarian cancers: results of a long-term follow-up study". Fertil Steril 71: 853-9. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/10231045?dopt=Abstract">PMID 10231045</a>. [<a rel="nofollow" class="external text" href="http://en.citizendium.org/wiki?title=CZ:Ref:DOI:&action=edit">e</a>]</cite> </li> <li id="cite_note-pmid17158751-54"><a href="#cite_ref-pmid17158751_54-0">↑</a> <cite style="font-style:normal">Rice S, Whitehead SA (2006). "Phytoestrogens and breast cancer--promoters or protectors?". Endocr Relat Cancer 13: 995-1015. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">DOI</a>:<a rel="nofollow" class="external text" href="https://dx.doi.org/10.1677/erc.1.01159">10.1677/erc.1.01159</a>. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/17158751?dopt=Abstract">PMID 17158751</a>. <a rel="nofollow" class="external text" href="http://researchblogging.org/post-search/list?search_text=10.1677/erc.1.01159">Research Blogging</a>.</cite> </li> <li id="cite_note-55"><a href="#cite_ref-55">↑</a> Gikas PD, Mokbel K (2005<a rel="nofollow" class="external text" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16526415&query_hl=5&itool=pubmed_docsum">Phytoestrogens and the risk of breast cancer: a review of the literature</a>. Int J Fertil Women's Med. </li> <li id="cite_note-Kauff_2002-56"><a href="#cite_ref-Kauff_2002_56-0">↑</a> <cite style="font-style:normal">Kauff N et al. (2002). <a rel="nofollow" class="external text" href="http://content.nejm.org/cgi/content/abstract/NEJMoa020119v1">"Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation"</a>. N Engl J Med 346: 1609-15. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/12023992?dopt=Abstract">PMID 12023992</a>.</cite> </li> <li id="cite_note-pmid19755347-57"><a href="#cite_ref-pmid19755347_57-0">↑</a> <cite style="font-style:normal">Nelson HD, Fu R, Griffin JC, Nygren P, Smith ME, Humphrey L (2009). <a rel="nofollow" class="external text" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=19755347">"Systematic Review: Comparative Effectiveness of Medications to Reduce Risk for Primary Breast Cancer."</a>. Ann Intern Med. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/19755347?dopt=Abstract">PMID 19755347</a>.</cite> </li> <li id="cite_note-pmid12093249-58"><a href="#cite_ref-pmid12093249_58-0">↑</a> <cite style="font-style:normal"> (2002) <a rel="nofollow" class="external text" href="http://www.annals.org/cgi/content/full/137/1/56">"Chemoprevention of breast cancer: recommendations and rationale"</a>. Ann Intern Med 137: 56-8. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/12093249?dopt=Abstract">PMID 12093249</a>. [<a rel="nofollow" class="external text" href="http://en.citizendium.org/wiki?title=CZ:Ref:DOI:&action=edit">e</a>]</cite> </li> <li id="cite_note-pmid12093250-59"><a href="#cite_ref-pmid12093250_59-0">↑</a> <cite style="font-style:normal">Kinsinger LS et al. (2002). <a rel="nofollow" class="external text" href="http://www.annals.org/cgi/content/full/137/1/59">"Chemoprevention of breast cancer: a summary of the evidence for the U.S. Preventive Services Task Force"</a>. Ann Intern Med 137: 59-69. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/12093250?dopt=Abstract">PMID 12093250</a>. [<a rel="nofollow" class="external text" href="http://en.citizendium.org/wiki?title=CZ:Ref:DOI:&action=edit">e</a>]</cite> </li> <li id="cite_note-pmid10376571-60"><a href="#cite_ref-pmid10376571_60-0">↑</a> <cite style="font-style:normal">Cummings SR et al. (1999). "The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation". JAMA 281: 2189-97. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/10376571?dopt=Abstract">PMID 10376571</a>. [<a rel="nofollow" class="external text" href="http://en.citizendium.org/wiki?title=CZ:Ref:DOI:&action=edit">e</a>]</cite> </li> <li id="cite_note-pmid16288118-61"><a href="#cite_ref-pmid16288118_61-0">↑</a> <cite style="font-style:normal">Fisher B et al. (2005). "Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study". J Natl Cancer Inst 97: 1652-62. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">DOI</a>:<a rel="nofollow" class="external text" href="https://dx.doi.org/10.1093/jnci/dji372">10.1093/jnci/dji372</a>. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/16288118?dopt=Abstract">PMID 16288118</a>. <a rel="nofollow" class="external text" href="http://researchblogging.org/post-search/list?search_text=10.1093/jnci/dji372">Research Blogging</a>.</cite> </li> <li id="cite_note-pmid9747868-62"><a href="#cite_ref-pmid9747868_62-0">↑</a> <cite style="font-style:normal">Fisher B et al. (1998). "Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study". J Natl Cancer Inst 90: 1371-88. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/9747868?dopt=Abstract">PMID 9747868</a>. [<a rel="nofollow" class="external text" href="http://en.citizendium.org/wiki?title=CZ:Ref:DOI:&action=edit">e</a>]</cite> </li> <li id="cite_note-pmid17470740-63"><a href="#cite_ref-pmid17470740_63-0">↑</a> <cite style="font-style:normal">Veronesi U, Maisonneuve P, Rotmensz N, et al (2007). "Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy". J Natl Cancer Inst 99: 727-37. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">DOI</a>:<a rel="nofollow" class="external text" href="https://dx.doi.org/10.1093/jnci/djk154">10.1093/jnci/djk154</a>. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/17470740?dopt=Abstract">PMID 17470740</a>. <a rel="nofollow" class="external text" href="http://researchblogging.org/post-search/list?search_text=10.1093/jnci/djk154">Research Blogging</a>.</cite> </li> <li id="cite_note-pmid17312304-64"><a href="#cite_ref-pmid17312304_64-0">↑</a> <cite style="font-style:normal">Cuzick J et al. (2007). "Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial". J Natl Cancer Inst 99: 272-82. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">DOI</a>:<a rel="nofollow" class="external text" href="https://dx.doi.org/10.1093/jnci/djk049">10.1093/jnci/djk049</a>. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/17312304?dopt=Abstract">PMID 17312304</a>. <a rel="nofollow" class="external text" href="http://researchblogging.org/post-search/list?search_text=10.1093/jnci/djk049">Research Blogging</a>.</cite> </li> <li id="cite_note-pmid16754727-65"><a href="#cite_ref-pmid16754727_65-0">↑</a> <cite style="font-style:normal">Vogel VG et al. (2006). "Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial". JAMA 295: 2727-41. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">DOI</a>:<a rel="nofollow" class="external text" href="https://dx.doi.org/10.1001/jama.295.23.joc60074">10.1001/jama.295.23.joc60074</a>. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/16754727?dopt=Abstract">PMID 16754727</a>. <a rel="nofollow" class="external text" href="http://researchblogging.org/post-search/list?search_text=10.1001/jama.295.23.joc60074">Research Blogging</a>.</cite> </li> <li id="cite_note-pmid16837676-66"><a href="#cite_ref-pmid16837676_66-0">↑</a> <cite style="font-style:normal">Barrett-Connor E et al. Raloxifene Use for The Heart (RUTH) Trial Investigators. (2006). "Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women". N Engl J Med 355: 125-37. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">DOI</a>:<a rel="nofollow" class="external text" href="https://dx.doi.org/10.1056/NEJMoa062462">10.1056/NEJMoa062462</a>. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/16837676?dopt=Abstract">PMID 16837676</a>. <a rel="nofollow" class="external text" href="http://researchblogging.org/post-search/list?search_text=10.1056/NEJMoa062462">Research Blogging</a>.</cite> </li> <li id="cite_note-pmid12359854-67"><a href="#cite_ref-pmid12359854_67-0">↑</a> <cite style="font-style:normal">Thomas DB et al. (2002). "Randomized trial of breast self-examination in Shanghai: final results". J Natl Cancer Inst 94: 1445-57. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/12359854?dopt=Abstract">PMID 12359854</a>. [<a rel="nofollow" class="external text" href="http://en.citizendium.org/wiki?title=CZ:Ref:DOI:&action=edit">e</a>]</cite> </li> <li id="cite_note-pmid12359843-68"><a href="#cite_ref-pmid12359843_68-0">↑</a> <cite style="font-style:normal">Harris R, Kinsinger LS (2002). "Routinely teaching breast self-examination is dead. What does this mean?". J. Natl. Cancer Inst. 94: 1420-1. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/12359843?dopt=Abstract">PMID 12359843</a>. [<a rel="nofollow" class="external text" href="http://en.citizendium.org/wiki?title=CZ:Ref:DOI:&action=edit">e</a>]</cite> </li> <li id="cite_note-pmid19720967-69"><a href="#cite_ref-pmid19720967_69-0">↑</a> <cite style="font-style:normal">Chiarelli AM, Majpruz V, Brown P, Thériault M, Shumak R, Mai V (2009). <a rel="nofollow" class="external text" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=19720967">"The contribution of clinical breast examination to the accuracy of breast screening."</a>. J Natl Cancer Inst 101 (18): 1236-43. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">DOI</a>:<a rel="nofollow" class="external text" href="https://dx.doi.org/10.1093/jnci/djp241">10.1093/jnci/djp241</a>. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/19720967?dopt=Abstract">PMID 19720967</a>. <a rel="nofollow" class="external text" href="http://researchblogging.org/post-search/list?search_text=10.1093/jnci/djp241">Research Blogging</a>.</cite> </li> <li id="cite_note-70"><a href="#cite_ref-70">↑</a> <cite style="font-style:normal">Elwood J, Cox B, Richardson A. "The effectiveness of breast cancer screening by mammography in younger women.". Online J Curr Clin Trials Doc No 32: [23,227 words; 195 paragraphs]. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/8305999?dopt=Abstract">PMID 8305999</a>.</cite> </li> <li id="cite_note-71"><a href="#cite_ref-71">↑</a> <cite style="font-style:normal">Fletcher S et al. (1993). "Report of the International Workshop on Screening for Breast Cancer.". J Natl Cancer Inst 85: 1644-56. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/8105098?dopt=Abstract">PMID 8105098</a>.</cite> </li> <li id="cite_note-Fletcher_1993-72"><a href="#cite_ref-Fletcher_1993_72-0">↑</a> <cite style="font-style:normal">Fletcher SW et al. (1993). "Report of the International Workshop on Screening for Breast Cancer". J Natl Cancer Inst 85: 1644-56. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/8105098?dopt=Abstract">PMID 8105098</a>. Retrieved on 2007-05-26. [<a rel="nofollow" class="external text" href="http://en.citizendium.org/wiki?title=CZ:Ref:DOI:&action=edit">e</a>]</cite> </li> <li id="cite_note-pmid21249649-73">↑ <a href="#cite_ref-pmid21249649_73-0">73.0</a> <a href="#cite_ref-pmid21249649_73-1">73.1</a> <cite style="font-style:normal">Gøtzsche PC, Nielsen M (2011). "Screening for breast cancer with mammography.". Cochrane Database Syst Rev 1: CD001877. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">DOI</a>:<a rel="nofollow" class="external text" href="https://dx.doi.org/10.1002/14651858.CD001877.pub4">10.1002/14651858.CD001877.pub4</a>. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/21249649?dopt=Abstract">PMID 21249649</a>. <a rel="nofollow" class="external text" href="http://researchblogging.org/post-search/list?search_text=10.1002/14651858.CD001877.pub4">Research Blogging</a>.</cite> </li> <li id="cite_note-pmid20068215-74"><a href="#cite_ref-pmid20068215_74-0">↑</a> <cite style="font-style:normal">DeAngelis CD, Fontanarosa PB (2010). <a rel="nofollow" class="external text" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&email=badgett@uthscdsa.edu&retmode=ref&cmd=prlinks&id=20068215">"US Preventive Services Task Force and breast cancer screening."</a>. JAMA 303 (2): 172-3. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">DOI</a>:<a rel="nofollow" class="external text" href="https://dx.doi.org/10.1001/jama.2009.1990">10.1001/jama.2009.1990</a>. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/20068215?dopt=Abstract">PMID 20068215</a>. <a rel="nofollow" class="external text" href="http://researchblogging.org/post-search/list?search_text=10.1001/jama.2009.1990">Research Blogging</a>.</cite> </li> <li id="cite_note-pmid19920272-75">↑ <a href="#cite_ref-pmid19920272_75-0">75.0</a> <a href="#cite_ref-pmid19920272_75-1">75.1</a> <cite style="font-style:normal">U.S. Preventive Services Task Force (2009). <a rel="nofollow" class="external text" href="http://www.annals.org/content/151/10/716.full">"Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement."</a>. Ann Intern Med 151 (10): 716-726. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">DOI</a>:<a rel="nofollow" class="external text" href="https://dx.doi.org/10.1059/0003-4819-151-10-200911170-00008">10.1059/0003-4819-151-10-200911170-00008</a>. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/19920272?dopt=Abstract">PMID 19920272</a>. <a rel="nofollow" class="external text" href="http://researchblogging.org/post-search/list?search_text=10.1059/0003-4819-151-10-200911170-00008">Research Blogging</a>.</cite> </li> <li id="cite_note-pmid19920273-76"><a href="#cite_ref-pmid19920273_76-0">↑</a> <cite style="font-style:normal">Nelson HD, Tyne K, Naik A, Bougatsos C, Chan BK, Humphrey L (2009). <a rel="nofollow" class="external text" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=19920273">"Screening for Breast Cancer: An Update for the U.S. Preventive Services Task Force."</a>. Ann Intern Med 151 (10): 727-737. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">DOI</a>:<a rel="nofollow" class="external text" href="https://dx.doi.org/10.1059/0003-4819-151-10-200911170-00009">10.1059/0003-4819-151-10-200911170-00009</a>. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/19920273?dopt=Abstract">PMID 19920273</a>. <a rel="nofollow" class="external text" href="http://researchblogging.org/post-search/list?search_text=10.1059/0003-4819-151-10-200911170-00009">Research Blogging</a>.</cite> </li> <li id="cite_note-pmid21916640-77"><a href="#cite_ref-pmid21916640_77-0">↑</a> <cite style="font-style:normal">Warner E (2011). "Clinical practice. Breast-cancer screening.". N Engl J Med 365 (11): 1025-32. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">DOI</a>:<a rel="nofollow" class="external text" href="https://dx.doi.org/10.1056/NEJMcp1101540">10.1056/NEJMcp1101540</a>. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/21916640?dopt=Abstract">PMID 21916640</a>. <a rel="nofollow" class="external text" href="http://researchblogging.org/post-search/list?search_text=10.1056/NEJMcp1101540">Research Blogging</a>.</cite> </li> <li id="cite_note-pmid21727289-78"><a href="#cite_ref-pmid21727289_78-0">↑</a> <cite style="font-style:normal">Schousboe JT, Kerlikowske K, Loh A, Cummings SR (2011). <a rel="nofollow" class="external text" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21727289">"Personalizing mammography by breast density and other risk factors for breast cancer: analysis of health benefits and cost-effectiveness."</a>. Ann Intern Med 155 (1): 10-20. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">DOI</a>:<a rel="nofollow" class="external text" href="https://dx.doi.org/10.1059/0003-4819-155-1-201107050-00003">10.1059/0003-4819-155-1-201107050-00003</a>. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/21727289?dopt=Abstract">PMID 21727289</a>. <a rel="nofollow" class="external text" href="http://researchblogging.org/post-search/list?search_text=10.1059/0003-4819-155-1-201107050-00003">Research Blogging</a>.</cite> </li> <li id="cite_note-pmid12204023-79">↑ <a href="#cite_ref-pmid12204023_79-0">79.0</a> <a href="#cite_ref-pmid12204023_79-1">79.1</a> <cite style="font-style:normal">Goodman SN (September 2002). <a rel="nofollow" class="external text" href="http://www.annals.org/cgi/pmidlookup?view=long&pmid=12204023">"The mammography dilemma: a crisis for evidence-based medicine?"</a>. Annals of internal medicine 137 (5 Part 1): 363–5. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/12204023?dopt=Abstract">PMID 12204023</a>. [<a rel="nofollow" class="external text" href="http://en.citizendium.org/wiki?title=CZ:Ref:DOI:&action=edit">e</a>]</cite> </li> <li id="cite_note-80"><a href="#cite_ref-80">↑</a> <a rel="nofollow" class="external text" href="http://news.bbc.co.uk/1/hi/health/1601267.stm">Women 'misjudge screening benefits'</a>, BBC, Monday, 15 October, 2001. Retrieved on 2007-04-04. </li> <li id="cite_note-pmid10675181-81"><a href="#cite_ref-pmid10675181_81-0">↑</a> <cite style="font-style:normal">Gøtzsche PC, Olsen O (2000). <a rel="nofollow" class="external text" href="http://linkinghub.elsevier.com/retrieve/pii/S0140-6736(99)06065-1">"Is screening for breast cancer with mammography justifiable?"</a>. Lancet 355: 129–34. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">DOI</a>:<a rel="nofollow" class="external text" href="https://dx.doi.org/10.1016/S0140-6736(99)06065-1">10.1016/S0140-6736(99)06065-1</a>. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/10675181?dopt=Abstract">PMID 10675181</a>. <a rel="nofollow" class="external text" href="http://researchblogging.org/post-search/list?search_text=10.1016/S0140-6736(99)06065-1">Research Blogging</a>.</cite> </li> <li id="cite_note-82"><a href="#cite_ref-82">↑</a> <cite style="font-style:normal">Olsen O, Gøtzsche P (2001). "Cochrane review on screening for breast cancer with mammography". Lancet 358 (9290): 1340-2. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/11684218?dopt=Abstract">PMID 11684218</a>.</cite> </li> <li id="cite_note-pmid17054145-83"><a href="#cite_ref-pmid17054145_83-0">↑</a> <cite style="font-style:normal">Gøtzsche PC, Nielsen M (2006). <a rel="nofollow" class="external text" href="https://dx.doi.org/10.1002/14651858.CD001877.pub2">"Screening for breast cancer with mammography"</a>. Cochrane database of systematic reviews (Online): CD001877. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">DOI</a>:<a rel="nofollow" class="external text" href="https://dx.doi.org/10.1002/14651858.CD001877.pub2">10.1002/14651858.CD001877.pub2</a>. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/17054145?dopt=Abstract">PMID 17054145</a>. <a rel="nofollow" class="external text" href="http://researchblogging.org/post-search/list?search_text=10.1002/14651858.CD001877.pub2">Research Blogging</a>.</cite> </li> <li id="cite_note-pmid12204020-84"><a href="#cite_ref-pmid12204020_84-0">↑</a> <cite style="font-style:normal">Humphrey LL et al. (September 2002). <a rel="nofollow" class="external text" href="http://www.annals.org/cgi/content/full/137/5_Part_1/347">"Breast cancer screening: a summary of the evidence for the U.S. Preventive Services Task Force"</a>. Annals of internal medicine 137: 347–60. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/12204020?dopt=Abstract">PMID 12204020</a>. [<a rel="nofollow" class="external text" href="http://en.citizendium.org/wiki?title=CZ:Ref:DOI:&action=edit">e</a>]</cite> </li> <li id="cite_note-pmid12204019-85"><a href="#cite_ref-pmid12204019_85-0">↑</a> <cite style="font-style:normal"> (2002) <a rel="nofollow" class="external text" href="http://www.annals.org/cgi/content/full/137/5_Part_1/344">"Screening for breast cancer: recommendations and rationale"</a>. Ann Internal Med 137: 344–6. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/12204019?dopt=Abstract">PMID 12204019</a>. [<a rel="nofollow" class="external text" href="http://en.citizendium.org/wiki?title=CZ:Ref:DOI:&action=edit">e</a>]</cite> </li> <li id="cite_note-pmid17404353-86"><a href="#cite_ref-pmid17404353_86-0">↑</a> <cite style="font-style:normal">Qaseem A et al. (2007). <a rel="nofollow" class="external text" href="http://www.annals.org/cgi/content/full/146/7/511">"Screening mammography for women 40 to 49 years of age: a clinical practice guideline from the American College of Physicians"</a>. Annals of internal medicine 146: 511–5. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/17404353?dopt=Abstract">PMID 17404353</a>. [<a rel="nofollow" class="external text" href="http://en.citizendium.org/wiki?title=CZ:Ref:DOI:&action=edit">e</a>]</cite> </li> <li id="cite_note-pmid17404354-87"><a href="#cite_ref-pmid17404354_87-0">↑</a> <cite style="font-style:normal">Armstrong K et al. (April 2007). <a rel="nofollow" class="external text" href="http://www.annals.org/cgi/content/full/146/7/516">"Screening mammography in women 40 to 49 years of age: a systematic review for the American College of Physicians"</a>. Annals of internal medicine 146: 516–26. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/17404354?dopt=Abstract">PMID 17404354</a>. [<a rel="nofollow" class="external text" href="http://en.citizendium.org/wiki?title=CZ:Ref:DOI:&action=edit">e</a>]</cite> </li> <li id="cite_note-titleBreast_Cancer_Screening_-_National_Cancer_Institute-88"><a href="#cite_ref-titleBreast_Cancer_Screening_-_National_Cancer_Institute_88-0">↑</a> <a rel="nofollow" class="external text" href="https://www.cancer.gov/cancertopics/pdq/screening/breast/HealthProfessional/page2">Breast Cancer Screening - National Cancer Institute</a>. Retrieved on 2008-03-03. </li> <li id="cite_note-pmid12809408-89"><a href="#cite_ref-pmid12809408_89-0">↑</a> <cite style="font-style:normal">Smith RA et al. (2003). <a rel="nofollow" class="external text" href="http://caonline.amcancersoc.org/cgi/pmidlookup?view=long&pmid=12809408">"American Cancer Society guidelines for breast cancer screening: update 2003"</a>. CA: a cancer journal for clinicians 53: 141–69. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/12809408?dopt=Abstract">PMID 12809408</a>. [<a rel="nofollow" class="external text" href="http://en.citizendium.org/wiki?title=CZ:Ref:DOI:&action=edit">e</a>]</cite> </li> <li id="cite_note-pmid15814020-90"><a href="#cite_ref-pmid15814020_90-0">↑</a> <cite style="font-style:normal">Smith-Bindman R et al. (2005). "Comparing the performance of mammography screening in the USA and the UK". Journal of medical screening 12: 50-4. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">DOI</a>:<a rel="nofollow" class="external text" href="https://dx.doi.org/10.1258/0969141053279130">10.1258/0969141053279130</a>. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/15814020?dopt=Abstract">PMID 15814020</a>. <a rel="nofollow" class="external text" href="http://researchblogging.org/post-search/list?search_text=10.1258/0969141053279130">Research Blogging</a>.</cite> </li> <li id="cite_note-pmid19589821-91"><a href="#cite_ref-pmid19589821_91-0">↑</a> <cite style="font-style:normal">Jørgensen KJ, Gøtzsche PC (2009). <a rel="nofollow" class="external text" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=19589821">"Overdiagnosis in publicly organised mammography screening programmes: systematic review of incidence trends."</a>. BMJ 339: b2587. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">DOI</a>:<a rel="nofollow" class="external text" href="https://dx.doi.org/10.1136/bmj.b2587">10.1136/bmj.b2587</a>. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/19589821?dopt=Abstract">PMID 19589821</a>. <a rel="nofollow" class="external text" href="http://researchblogging.org/post-search/list?search_text=10.1136/bmj.b2587">Research Blogging</a>.</cite> </li> <li id="cite_note-pmid15070793-92"><a href="#cite_ref-pmid15070793_92-0">↑</a> <cite style="font-style:normal">Burstein HJ, Polyak K, Wong JS, Lester SC, Kaelin CM (2004). <a rel="nofollow" class="external text" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15070793">"Ductal carcinoma in situ of the breast."</a>. N Engl J Med 350 (14): 1430-41. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">DOI</a>:<a rel="nofollow" class="external text" href="https://dx.doi.org/10.1056/NEJMra031301">10.1056/NEJMra031301</a>. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/15070793?dopt=Abstract">PMID 15070793</a>. <a rel="nofollow" class="external text" href="http://researchblogging.org/post-search/list?search_text=10.1056/NEJMra031301">Research Blogging</a>.</cite> </li> <li id="cite_note-pmid12204013-93"><a href="#cite_ref-pmid12204013_93-0">↑</a> <cite style="font-style:normal">Miller AB, To T, Baines CJ, Wall C (2002). <a rel="nofollow" class="external text" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12204013">"The Canadian National Breast Screening Study-1: breast cancer mortality after 11 to 16 years of follow-up. A randomized screening trial of mammography in women age 40 to 49 years."</a>. Ann Intern Med 137 (5 Part 1): 305-12. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/12204013?dopt=Abstract">PMID 12204013</a>. [<a rel="nofollow" class="external text" href="http://en.citizendium.org/wiki?title=CZ:Ref:DOI:&action=edit">e</a>]</cite> <a rel="nofollow" class="external text" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12614123">Review in: ACP J Club. 2003 Mar-Apr;138(2):38-39</a> </li> <li id="cite_note-94"><a href="#cite_ref-94">↑</a> <cite style="font-style:normal">Hrung J et al. (1999). "Accuracy of MR imaging in the work-up of suspicious breast lesions: a diagnostic meta-analysis.". Acad Radiol 6: 387-97. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/10410164?dopt=Abstract">PMID 10410164</a>.</cite> </li> <li id="cite_note-95"><a href="#cite_ref-95">↑</a> <cite style="font-style:normal">Morrow M (2004). "Magnetic resonance imaging in breast cancer: one step forward, two steps back?". JAMA 292: 2779-80. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/15585740?dopt=Abstract">PMID 15585740</a>.</cite> </li> <li id="cite_note-pmid18477782-96"><a href="#cite_ref-pmid18477782_96-0">↑</a> <cite style="font-style:normal">Berg WA, Blume JD, Cormack JB, Mendelson EB, Lehrer D, Böhm-Vélez M et al. (2008). <a rel="nofollow" class="external text" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18477782">"Combined screening with ultrasound and mammography vs mammography alone in women at elevated risk of breast cancer."</a>. JAMA 299 (18): 2151-63. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">DOI</a>:<a rel="nofollow" class="external text" href="https://dx.doi.org/10.1001/jama.299.18.2151">10.1001/jama.299.18.2151</a>. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/18477782?dopt=Abstract">PMID 18477782</a>. PMC <a rel="nofollow" class="external text" href="http://www.pubmedcentral.nih.gov/articlerender.fcgi?pubmedid=18477782">PMC2718688</a>. <a rel="nofollow" class="external text" href="http://researchblogging.org/post-search/list?search_text=10.1001/jama.299.18.2151">Research Blogging</a>.</cite> <a rel="nofollow" class="external text" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18697289">Review in: J Fam Pract. 2008 Aug;57(8):508</a> </li> <li id="cite_note-pmid22474203-97">↑ <a href="#cite_ref-pmid22474203_97-0">97.0</a> <a href="#cite_ref-pmid22474203_97-1">97.1</a> <cite style="font-style:normal">Berg WA, Zhang Z, Lehrer D, Jong RA, Pisano ED, Barr RG et al. (2012). <a rel="nofollow" class="external text" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22474203">"Detection of breast cancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk."</a>. JAMA 307 (13): 1394-404. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">DOI</a>:<a rel="nofollow" class="external text" href="https://dx.doi.org/10.1001/jama.2012.388">10.1001/jama.2012.388</a>. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/22474203?dopt=Abstract">PMID 22474203</a>. <a rel="nofollow" class="external text" href="http://researchblogging.org/post-search/list?search_text=10.1001/jama.2012.388">Research Blogging</a>.</cite> </li> <li id="cite_note-pmid16144894-98"><a href="#cite_ref-pmid16144894_98-0">↑</a> <cite style="font-style:normal">U.S. Preventive Services Task Force (2005). <a rel="nofollow" class="external text" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=16144894">"Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement."</a>. Ann Intern Med 143 (5): 355-61. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/16144894?dopt=Abstract">PMID 16144894</a>.</cite> <a rel="nofollow" class="external text" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=16539352">Review in: ACP J Club. 2006 Mar-Apr;144(2):37</a> </li> <li id="cite_note-99"><a href="#cite_ref-99">↑</a> U.S. Preventive Services Task Force (2005). <a rel="nofollow" class="external text" href="https://www.uspreventiveservicestaskforce.org/uspstf05/brcagen/brcagenrs.htm">Genetic Risk Assessment and BRCA Mutation Testing for Breast and Ovarian Cancer Susceptibility</a> </li> <li id="cite_note-100"><a href="#cite_ref-100">↑</a> Rusiecki JA, Holford TR, Zahm SH, Zheng T. Breast cancer risk factors according to joint estrogen receptor and progesterone receptor status. Cancer Detect Prev 2005;29:419-26 </li> <li id="cite_note-101"><a href="#cite_ref-101">↑</a> <a rel="nofollow" class="external text" href="https://www.cancer.gov/cancertopics/factsheet/therapy/herceptin,">accessed 1/30/07 cancer.gov</a> </li> <li id="cite_note-102"><a href="#cite_ref-102">↑</a> Marchionni et al. (2008) <a rel="nofollow" class="external text" href="http://www.annals.org/cgi/content/abstract/148/5/358">Systematic Review: Gene Expression Profiling Assays in Early-Stage Breast Cancer</a>. Ann Intern Med' 148:358-69 </li> <li id="cite_note-pmid16720680-103"><a href="#cite_ref-pmid16720680_103-0">↑</a> <cite style="font-style:normal">Paik S et al. (2006). "Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer". J Clin Oncol 24: 3726–34. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">DOI</a>:<a rel="nofollow" class="external text" href="https://dx.doi.org/10.1200/JCO.2005.04.7985">10.1200/JCO.2005.04.7985</a>. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/16720680?dopt=Abstract">PMID 16720680</a>. <a rel="nofollow" class="external text" href="http://researchblogging.org/post-search/list?search_text=10.1200/JCO.2005.04.7985">Research Blogging</a>.</cite> </li> <li id="cite_note-NewsMax-104"><a href="#cite_ref-NewsMax_104-0">↑</a> "<a rel="nofollow" class="external text" href="http://newsmax.com/archives/articles/2007/2/6/130740.shtml">FDA Approves New Breast Cancer Test</a>". <a href="/wiki/index.php?title=Associated_Press&action=edit&redlink=1" class="new" title="Associated Press (page does not exist)">Associated Press</a>, February 6, 2007. </li> <li id="cite_note-Bennett_2006-105">↑ <a href="#cite_ref-Bennett_2006_105-0">105.0</a> <a href="#cite_ref-Bennett_2006_105-1">105.1</a> <cite style="font-style:normal"> (2006) <a rel="nofollow" class="external text" href="http://www.accc-cancer.org/onis/articles/marapr06/bennett.pdf">"Sentinel Lymph Node Biopsy for Breast Cancer and Melanoma"</a>. Oncology Issues March/April: 22–5.</cite> </li> <li id="cite_note-106"><a href="#cite_ref-106">↑</a> <a rel="nofollow" class="external text" href="https://www.cancer.gov/cancertopics/pdq/treatment/breast/HealthProfessional/page7#Section_251">cancer.gov</a> </li> <li id="cite_note-107"><a href="#cite_ref-107">↑</a> Vaidya J. <a rel="nofollow" class="external text" href="http://www.dundee.ac.uk/surgery/targit/targitpapers.htm">TARGIT (TARGeted Intraoperative radioTherapy)</a>. Retrieved on 2007-03-11. </li> <li id="cite_note-Vaidya_2000-108"><a href="#cite_ref-Vaidya_2000_108-0">↑</a> Vaidya J et al.. <a rel="nofollow" class="external text" href="http://www.thelancet.com/journals/lancet/misc/protocol/99PRT-47">Protocol 99PRT/47 Targeted Intraoperative radiotherapy (Targit) for breast cancer</a>. Retrieved on 2007-03-11. </li> <li id="cite_note-Vaidya_2006-109"><a href="#cite_ref-Vaidya_2006_109-0">↑</a> <cite style="font-style:normal">Vaidya J et al. (2006). "Targeted intraoperative radiotherapy (TARGIT) yields very low recurrence rates when given as a boost". Int J Radiat Oncol Biol Phys 66: 1335-8. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/17084562?dopt=Abstract">PMID 17084562</a>.</cite> </li> <li id="cite_note-110"><a href="#cite_ref-110">↑</a> <a rel="nofollow" class="external text" href="http://www.dundee.ac.uk/surgery/targit/targitpapers.htm">Targit literature Website</a> </li> <li id="cite_note-111"><a href="#cite_ref-111">↑</a> <cite style="font-style:normal" class="external text" id="CITEREFGreenspan,_E._M.,_Fieber,_M.,_Lestrick,_G.,_and_Edelman,_S.1963">Greenspan, E. M., Fieber, M., Lestrick, G., and Edelman, S. (1963), "Response of Advanced Breast Carcinoma to the Combination of the Anti-metabolite Methotrexate and the Alkylating Agent, Thio-TEPA", J. Mt. Sinai Hosp. N.Y 30: 246-267</cite> </li> <li id="cite_note-112"><a href="#cite_ref-112">↑</a> <cite style="font-style:normal" class="external text" id="CITEREFCooper,_R._G.1969">Cooper, R. G. (1969), "Combination Chemotherapy in Hormone Resistant Breast Cancer.", Proc. Am. Assoc. Cancer Res. 10 (15)</cite> </li> <li id="cite_note-113"><a href="#cite_ref-113">↑</a> <cite style="font-style:normal" class="external text" id="CITEREFRichard_V._Smalley_for_the_Southeastern_Cancer_Research_Group1976">Richard V. Smalley for the Southeastern Cancer Research Group (November 1976), "<a rel="nofollow" class="external text" href="http://cancerres.aacrjournals.org/cgi/reprint/36/11_Part_1/3911.pdf">Combination versus Sequential Five-Drug Chemotherapy in Metastatic Carcinoma of the Breast</a>", Cancer Research 36: 3911-3916</cite> </li> <li id="cite_note-114"><a href="#cite_ref-114">↑</a> <cite style="font-style:normal" class="external text" id="CITEREFHyman_B._Muss,_''et_al.''1978">Hyman B. Muss, et al. (1978), Cancer 42 (5): 2141-2148</cite> </li> <li id="cite_note-115"><a href="#cite_ref-115">↑</a> <a rel="nofollow" class="external text" href="http://news.bbc.co.uk/2/hi/health/6646193.stm">Breast tumour drug target found</a>, BBC News, 20 May 2007 </li> <li id="cite_note-pmid17611206-116"><a href="#cite_ref-pmid17611206_116-0">↑</a> <cite style="font-style:normal">Hudis CA (2007). <a rel="nofollow" class="external text" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=17611206">"Trastuzumab--mechanism of action and use in clinical practice."</a>. N Engl J Med 357 (1): 39-51. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">DOI</a>:<a rel="nofollow" class="external text" href="https://dx.doi.org/10.1056/NEJMra043186">10.1056/NEJMra043186</a>. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/17611206?dopt=Abstract">PMID 17611206</a>. <a rel="nofollow" class="external text" href="http://researchblogging.org/post-search/list?search_text=10.1056/NEJMra043186">Research Blogging</a>.</cite> </li> <li id="cite_note-pmid16236738-117"><a href="#cite_ref-pmid16236738_117-0">↑</a> <cite style="font-style:normal">Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE et al. (2005). <a rel="nofollow" class="external text" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=16236738">"Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer."</a>. N Engl J Med 353 (16): 1673-84. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">DOI</a>:<a rel="nofollow" class="external text" href="https://dx.doi.org/10.1056/NEJMoa052122">10.1056/NEJMoa052122</a>. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/16236738?dopt=Abstract">PMID 16236738</a>. <a rel="nofollow" class="external text" href="http://researchblogging.org/post-search/list?search_text=10.1056/NEJMoa052122">Research Blogging</a>.</cite> </li> <li id="cite_note-AP-118"><a href="#cite_ref-AP_118-0">↑</a> <cite style="font-style:normal" class="external text" id="CITEREFMatthew_Perone2010">Matthew Perone (17 July 2010), <a rel="nofollow" class="external text" href="http://www.washingtonpost.com/wp-dyn/content/article/2010/07/17/AR2010071700813_pf.html">FDA says breast cancer drug did not extend lives</a>, <a href="/wiki/index.php?title=Associated_Press&action=edit&redlink=1" class="new" title="Associated Press (page does not exist)">Associated Press</a> in <a href="/wiki/Washington_Post" title="Washington Post">Washington Post</a></cite> </li> <li id="cite_note-pmid21951942-119"><a href="#cite_ref-pmid21951942_119-0">↑</a> <cite style="font-style:normal">Robertson C, Arcot Ragupathy SK, Boachie C, Dixon JM, Fraser C, Hernández R et al. (2011). <a rel="nofollow" class="external text" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21951942">"The clinical effectiveness and cost-effectiveness of different surveillance mammography regimens after the treatment for primary breast cancer: systematic reviews registry database analyses and economic evaluation."</a>. Health Technol Assess 15 (34): v-vi, 1-322. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">DOI</a>:<a rel="nofollow" class="external text" href="https://dx.doi.org/10.3310/hta15340">10.3310/hta15340</a>. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/21951942?dopt=Abstract">PMID 21951942</a>. <a rel="nofollow" class="external text" href="http://researchblogging.org/post-search/list?search_text=10.3310/hta15340">Research Blogging</a>.</cite> </li> <li id="cite_note-pmid15674884-120"><a href="#cite_ref-pmid15674884_120-0">↑</a> <cite style="font-style:normal">Rojas MP, Telaro E, Russo A, Moschetti I, Coe L, Fossati R et al. (2005). <a rel="nofollow" class="external text" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15674884">"Follow-up strategies for women treated for early breast cancer."</a>. Cochrane Database Syst Rev (1): CD001768. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">DOI</a>:<a rel="nofollow" class="external text" href="https://dx.doi.org/10.1002/14651858.CD001768.pub2">10.1002/14651858.CD001768.pub2</a>. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/15674884?dopt=Abstract">PMID 15674884</a>. <a rel="nofollow" class="external text" href="http://researchblogging.org/post-search/list?search_text=10.1002/14651858.CD001768.pub2">Research Blogging</a>.</cite> </li> <li id="cite_note-pmid10551200-121">↑ <a href="#cite_ref-pmid10551200_121-0">121.0</a> <a href="#cite_ref-pmid10551200_121-1">121.1</a> <cite style="font-style:normal">Temple LK, Wang EE, McLeod RS (1999). <a rel="nofollow" class="external text" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10551200">"Preventive health care, 1999 update: 3. Follow-up after breast cancer. Canadian Task Force on Preventive Health Care."</a>. CMAJ 161 (8): 1001-8. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/10551200?dopt=Abstract">PMID 10551200</a>. PMC <a rel="nofollow" class="external text" href="http://www.pubmedcentral.nih.gov/articlerender.fcgi?pubmedid=10551200">PMC1230673</a>. [<a rel="nofollow" class="external text" href="http://en.citizendium.org/wiki?title=CZ:Ref:DOI:&action=edit">e</a>]</cite> </li> <li id="cite_note-pmid23129741-122"><a href="#cite_ref-pmid23129741_122-0">↑</a> <cite style="font-style:normal">Khatcheressian JL, Hurley P, Bantug E, Esserman LJ, Grunfeld E, Halberg F et al. (2013). <a rel="nofollow" class="external text" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23129741">"Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update."</a>. J Clin Oncol 31 (7): 961-5. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">DOI</a>:<a rel="nofollow" class="external text" href="https://dx.doi.org/10.1200/JCO.2012.45.9859">10.1200/JCO.2012.45.9859</a>. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/23129741?dopt=Abstract">PMID 23129741</a>. <a rel="nofollow" class="external text" href="http://researchblogging.org/post-search/list?search_text=10.1200/JCO.2012.45.9859">Research Blogging</a>.</cite> </li> <li id="cite_note-pmid19119079-123"><a href="#cite_ref-pmid19119079_123-0">↑</a> <cite style="font-style:normal">Sheppard C, Higgins B, Wise M, Yiangou C, Dubois D, Kilburn S (2009). <a rel="nofollow" class="external text" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19119079">"Breast cancer follow up: a randomised controlled trial comparing point of need access versus routine 6-monthly clinical review."</a>. Eur J Oncol Nurs 13 (1): 2-8. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">DOI</a>:<a rel="nofollow" class="external text" href="https://dx.doi.org/10.1016/j.ejon.2008.11.005">10.1016/j.ejon.2008.11.005</a>. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/19119079?dopt=Abstract">PMID 19119079</a>. <a rel="nofollow" class="external text" href="http://researchblogging.org/post-search/list?search_text=10.1016/j.ejon.2008.11.005">Research Blogging</a>.</cite> </li> <li id="cite_note-pmid8182811-124"><a href="#cite_ref-pmid8182811_124-0">↑</a> <cite style="font-style:normal"> (1994) <a rel="nofollow" class="external text" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8182811">"Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial. The GIVIO Investigators."</a>. JAMA 271 (20): 1587-92. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/8182811?dopt=Abstract">PMID 8182811</a>. [<a rel="nofollow" class="external text" href="http://en.citizendium.org/wiki?title=CZ:Ref:DOI:&action=edit">e</a>]</cite> </li> <li id="cite_note-pmid24627271-125"><a href="#cite_ref-pmid24627271_125-0">↑</a> <cite style="font-style:normal">Henry NL, Henry LN, Hayes DF, Ramsey SD, Hortobagyi GN, Barlow WE et al. (2014). <a rel="nofollow" class="external text" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24627271">"Promoting quality and evidence-based care in early-stage breast cancer follow-up."</a>. J Natl Cancer Inst 106 (4): dju034. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">DOI</a>:<a rel="nofollow" class="external text" href="https://dx.doi.org/10.1093/jnci/dju034">10.1093/jnci/dju034</a>. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/24627271?dopt=Abstract">PMID 24627271</a>. <a rel="nofollow" class="external text" href="http://researchblogging.org/post-search/list?search_text=10.1093/jnci/dju034">Research Blogging</a>.</cite> </li> <li id="cite_note-pmid24726438-126"><a href="#cite_ref-pmid24726438_126-0">↑</a> <cite style="font-style:normal">Puglisi F, Fontanella C, Numico G, Sini V, Evangelista L, Monetti F et al. (2014). <a rel="nofollow" class="external text" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24726438">"Follow-up of patients with early breast cancer: is it time to rewrite the story?"</a>. Crit Rev Oncol Hematol 91 (2): 130-41. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">DOI</a>:<a rel="nofollow" class="external text" href="https://dx.doi.org/10.1016/j.critrevonc.2014.03.001">10.1016/j.critrevonc.2014.03.001</a>. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/24726438?dopt=Abstract">PMID 24726438</a>. <a rel="nofollow" class="external text" href="http://researchblogging.org/post-search/list?search_text=10.1016/j.critrevonc.2014.03.001">Research Blogging</a>.</cite> </li> <li id="cite_note-pmid25329669-127"><a href="#cite_ref-pmid25329669_127-0">↑</a> <cite style="font-style:normal">Jacobs C, Graham ID, Makarski J, Chassé M, Fergusson D, Hutton B et al. (2014). <a rel="nofollow" class="external text" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25329669">"Clinical practice guidelines and consensus statements in oncology--an assessment of their methodological quality."</a>. PLoS One 9 (10): e110469. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">DOI</a>:<a rel="nofollow" class="external text" href="https://dx.doi.org/10.1371/journal.pone.0110469">10.1371/journal.pone.0110469</a>. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/25329669?dopt=Abstract">PMID 25329669</a>. PMC <a rel="nofollow" class="external text" href="http://www.pubmedcentral.nih.gov/articlerender.fcgi?pubmedid=25329669">PMC4201546</a>. <a rel="nofollow" class="external text" href="http://researchblogging.org/post-search/list?search_text=10.1371/journal.pone.0110469">Research Blogging</a>.</cite> </li> <li id="cite_note-128"><a href="#cite_ref-128">↑</a> Ali Fawzi, MD (June 2006). <a rel="nofollow" class="external text" href="http://www.emedicine.com/plastic/topic125.htm">Gynecomastia</a>. eMedicine.com. Retrieved on 2007-04-17. </li> <li id="cite_note-AMN-129"><a href="#cite_ref-AMN_129-0">↑</a> Armando E. Giuliano, MD (May 31 2006). <a rel="nofollow" class="external text" href="http://www.health.am/cr/more/carcinoma-of-the-male-breast/">Carcinoma of the Male Breast - General Considerations</a>. Breast Cancer. Armenian Health Network, Health.am. Retrieved on 2007-02-27. </li> </ol></div></div>  </div> <div class="printfooter" data-nosnippet="">Retrieved from "<a dir="ltr" href="https://citizendium.org/wiki/index.php?title=Breast_cancer&oldid=979686">https://citizendium.org/wiki/index.php?title=Breast_cancer&oldid=979686</a>"</div></div> <div id="catlinks" class="catlinks" data-mw="interface"><div id="mw-normal-catlinks" class="mw-normal-catlinks"><a href="/wiki/Special:Categories" title="Special:Categories">Categories</a>: <ul><li><a href="/wiki/Category:Pages_using_PMID_magic_links" title="Category:Pages using PMID magic links">Pages using PMID magic links</a></li><li><a href="/wiki/Category:CZ_Live" title="Category:CZ Live">CZ Live</a></li><li><a href="/wiki/Category:Health_Sciences_Workgroup" title="Category:Health Sciences Workgroup">Health Sciences Workgroup</a></li><li><a href="/wiki/Category:Biology_Workgroup" title="Category:Biology Workgroup">Biology Workgroup</a></li><li><a href="/wiki/Category:Oncology_Subgroup" title="Category:Oncology Subgroup">Oncology Subgroup</a></li><li><a href="/wiki/Category:Obstetrics_and_gynecology_Subgroup" title="Category:Obstetrics and gynecology Subgroup">Obstetrics and gynecology Subgroup</a></li><li><a href="/wiki/Category:Articles_written_in_British_English" title="Category:Articles written in British English">Articles written in British English</a></li><li><a href="/wiki/Category:All_Content" title="Category:All Content">All Content</a></li><li><a href="/wiki/Category:Health_Sciences_Content" title="Category:Health Sciences Content">Health Sciences Content</a></li><li><a href="/wiki/Category:Biology_Content" title="Category:Biology Content">Biology Content</a></li><li><a href="/wiki/index.php?title=Category:Oncology_tag&action=edit&redlink=1" class="new" title="Category:Oncology tag (page does not exist)">Oncology tag</a></li><li><a href="/wiki/index.php?title=Category:Obstetrics_and_gynecology_tag&action=edit&redlink=1" class="new" title="Category:Obstetrics and gynecology tag (page does not exist)">Obstetrics and gynecology tag</a></li><li><a href="/wiki/Category:Internal_articles_including_external_material" title="Category:Internal articles including external material">Internal articles including external material</a></li><li><a href="/wiki/Category:Flagged_for_Review" title="Category:Flagged for Review">Flagged for Review</a></li><li><a href="/wiki/Category:Pages_with_too_many_expensive_parser_function_calls" title="Category:Pages with too many expensive parser function calls">Pages with too many expensive parser function calls</a></li></ul></div><div id="mw-hidden-catlinks" class="mw-hidden-catlinks mw-hidden-cats-hidden">Hidden categories: <ul><li><a href="/wiki/Category:Health_Sciences_tag" title="Category:Health Sciences tag">Health Sciences tag</a></li><li><a href="/wiki/Category:Biology_tag" title="Category:Biology tag">Biology tag</a></li><li><a href="/wiki/Category:Suggestion_Bot_Tag" title="Category:Suggestion Bot Tag">Suggestion Bot Tag</a></li></ul></div></div> </div> </div> <div id="mw-navigation"> <h2>Navigation menu</h2> <div id="mw-head"> <nav id="p-personal" class="vector-menu mw-portlet mw-portlet-personal vector-user-menu-legacy" aria-labelledby="p-personal-label" role="navigation" > <h3 id="p-personal-label" class="vector-menu-heading " > Personal tools </h3> <div class="vector-menu-content"> <ul class="vector-menu-content-list"><li id="pt-login" class="mw-list-item"><a href="/wiki/index.php?title=Special:UserLogin&returnto=Breast+cancer" title="To edit pages, [[Special:RequestAccount|get a contributor account]]. [o]" accesskey="o">Log in</a></li></ul> </div> </nav> <div id="left-navigation"> <nav id="p-namespaces" class="vector-menu mw-portlet mw-portlet-namespaces vector-menu-tabs vector-menu-tabs-legacy" aria-labelledby="p-namespaces-label" role="navigation" > <h3 id="p-namespaces-label" class="vector-menu-heading " > Namespaces </h3> <div class="vector-menu-content"> <ul class="vector-menu-content-list"><li id="ca-nstab-main" class="selected mw-list-item"><a href="/wiki/Breast_cancer" title="View the content page [c]" accesskey="c">Page</a></li><li id="ca-talk" class="mw-list-item"><a href="/wiki/Talk:Breast_cancer" rel="discussion" title="Discussion about the content page [t]" accesskey="t">Discussion</a></li></ul> </div> </nav> <nav id="p-variants" class="vector-menu mw-portlet mw-portlet-variants emptyPortlet vector-menu-dropdown" aria-labelledby="p-variants-label" role="navigation" > <input type="checkbox" id="p-variants-checkbox" role="button" aria-haspopup="true" data-event-name="ui.dropdown-p-variants" class="vector-menu-checkbox" aria-labelledby="p-variants-label" /> <label id="p-variants-label" aria-label="Change language variant" class="vector-menu-heading " > English </label> <div class="vector-menu-content"> <ul class="vector-menu-content-list"></ul> </div> </nav> </div> <div id="right-navigation"> <nav id="p-views" class="vector-menu mw-portlet mw-portlet-views vector-menu-tabs vector-menu-tabs-legacy" aria-labelledby="p-views-label" role="navigation" > <h3 id="p-views-label" class="vector-menu-heading " > Views </h3> <div class="vector-menu-content"> <ul class="vector-menu-content-list"><li id="ca-view" class="selected mw-list-item"><a href="/wiki/Breast_cancer">Read</a></li><li id="ca-viewsource" class="mw-list-item"><a href="/wiki/index.php?title=Breast_cancer&action=edit" title="This page is protected.
You can view its source [e]" accesskey="e">View source</a></li><li id="ca-history" class="mw-list-item"><a href="/wiki/index.php?title=Breast_cancer&action=history" title="Past revisions of this page [h]" accesskey="h">View history</a></li><li id="ca-mzwi" class="mw-list-item"><a href="/wiki/index.php?title=Breast_cancer&action=mzwi">ZWI Export</a></li></ul> </div> </nav> <nav id="p-cactions" class="vector-menu mw-portlet mw-portlet-cactions emptyPortlet vector-menu-dropdown" aria-labelledby="p-cactions-label" role="navigation" title="More options" > <input type="checkbox" id="p-cactions-checkbox" role="button" aria-haspopup="true" data-event-name="ui.dropdown-p-cactions" class="vector-menu-checkbox" aria-labelledby="p-cactions-label" /> <label id="p-cactions-label" class="vector-menu-heading " > More </label> <div class="vector-menu-content"> <ul class="vector-menu-content-list"></ul> </div> </nav> <div id="p-search" role="search" class="vector-search-box-vue vector-search-box-show-thumbnail vector-search-box-auto-expand-width vector-search-box"> <div> <h3 > <label for="searchInput">Search</label> </h3> <form action="/wiki/index.php" id="searchform" class="vector-search-box-form"> <div id="simpleSearch" class="vector-search-box-inner" data-search-loc="header-navigation"> <input class="vector-search-box-input" type="search" name="search" placeholder="Search Citizendium" aria-label="Search Citizendium" autocapitalize="sentences" title="Search Citizendium [f]" accesskey="f" id="searchInput" > <input type="hidden" name="title" value="Special:Search"> <input id="mw-searchButton" class="searchButton mw-fallbackSearchButton" type="submit" name="fulltext" title="Search the pages for this text" value="Search"> <input id="searchButton" class="searchButton" type="submit" name="go" title="Go to a page with this exact name if it exists" value="Go To Page"> </div> </form> </div> </div> </div> </div> <div id="mw-panel"> <div id="p-logo" role="banner"> <a class="mw-wiki-logo" href="/wiki/Welcome_to_Citizendium" title="Visit the main page"></a> </div> <nav id="p-Read" class="vector-menu mw-portlet mw-portlet-Read vector-menu-portal portal" aria-labelledby="p-Read-label" role="navigation" > <h3 id="p-Read-label" class="vector-menu-heading " > Read </h3> <div class="vector-menu-content"> <ul class="vector-menu-content-list"><li id="n-mainpage" class="mw-list-item"><a href="/wiki/Welcome_to_Citizendium" title="Visit the main page [z]" accesskey="z">Welcome to Citizendium</a></li><li id="n-Citable-Articles" class="mw-list-item"><a href="/wiki/Category:Citable_versions_of_articles">Citable Articles</a></li><li id="n-All-Articles" class="mw-list-item"><a href="/wiki/Category:CZ_Live">All Articles</a></li><li id="n-Random-Article" class="mw-list-item"><a href="/wiki/Special:RandomInCategory/CZ_Live">Random Article</a></li><li id="n-All-Recent-Changes" class="mw-list-item"><a href="/wiki/Special:RecentChanges">All Recent Changes</a></li></ul> </div> </nav> <nav id="p-About_Us" class="vector-menu mw-portlet mw-portlet-About_Us vector-menu-portal portal" aria-labelledby="p-About_Us-label" role="navigation" > <h3 id="p-About_Us-label" class="vector-menu-heading " > About Us </h3> <div class="vector-menu-content"> <ul class="vector-menu-content-list"><li id="n-Introduction" class="mw-list-item"><a href="/wiki/CZ:About">Introduction</a></li><li id="n-FAQ" class="mw-list-item"><a href="/wiki/CZ:FAQ">FAQ</a></li><li id="n-Policies" class="mw-list-item"><a href="/wiki/CZ:Policies">Policies</a></li><li id="n-Governance" class="mw-list-item"><a href="/wiki/CZ:Governance">Governance</a></li></ul> </div> </nav> <nav id="p-Contact_Us" class="vector-menu mw-portlet mw-portlet-Contact_Us vector-menu-portal portal" aria-labelledby="p-Contact_Us-label" role="navigation" > <h3 id="p-Contact_Us-label" class="vector-menu-heading " > Contact Us </h3> <div class="vector-menu-content"> <ul class="vector-menu-content-list"><li id="n-Enquiries" class="mw-list-item"><a href="/wiki/CZ:Enquiry_Form">Enquiries</a></li><li id="n-Apply-to-Join" class="mw-list-item"><a href="/wiki/Help:Index/Join">Apply to Join</a></li><li id="n-Personnel" class="mw-list-item"><a href="/wiki/CZ:Personnel">Personnel</a></li></ul> </div> </nav> <nav id="p-How_To" class="vector-menu mw-portlet mw-portlet-How_To vector-menu-portal portal" aria-labelledby="p-How_To-label" role="navigation" > <h3 id="p-How_To-label" class="vector-menu-heading " > How To </h3> <div class="vector-menu-content"> <ul class="vector-menu-content-list"><li id="n-Forum" class="mw-list-item"><a href="/wiki/Forum:Home">Forum</a></li><li id="n-Start-Article" class="mw-list-item"><a href="/wiki/CZ:Start_Article">Start Article</a></li><li id="n-Article-Mechanics" class="mw-list-item"><a href="/wiki/CZ:Article_mechanics">Article Mechanics</a></li><li id="n-How-to-Edit" class="mw-list-item"><a href="/wiki/CZ:How_to_edit_an_article">How to Edit</a></li><li id="n-Help" class="mw-list-item"><a href="/wiki/CZ:Home">Help</a></li><li id="n-More-Help" class="mw-list-item"><a href="/wiki/Help:Index">More Help</a></li></ul> </div> </nav> <nav id="p-Finance" class="vector-menu mw-portlet mw-portlet-Finance vector-menu-portal portal" aria-labelledby="p-Finance-label" role="navigation" > <h3 id="p-Finance-label" class="vector-menu-heading " > Finance </h3> <div class="vector-menu-content"> <ul class="vector-menu-content-list"><li id="n-Financial-Report" class="mw-list-item"><a href="/wiki/CZ:Financial_report">Financial Report</a></li><li id="n-Donate" class="mw-list-item"><a href="/wiki/CZ:Donate">Donate</a></li></ul> </div> </nav> <nav id="p-tb" class="vector-menu mw-portlet mw-portlet-tb vector-menu-portal portal" aria-labelledby="p-tb-label" role="navigation" > <h3 id="p-tb-label" class="vector-menu-heading " > Tools </h3> <div class="vector-menu-content"> <ul class="vector-menu-content-list"><li id="t-whatlinkshere" class="mw-list-item"><a href="/wiki/Special:WhatLinksHere/Breast_cancer" title="A list of all wiki pages that link here [j]" accesskey="j">What links here</a></li><li id="t-recentchangeslinked" class="mw-list-item"><a href="/wiki/Special:RecentChangesLinked/Breast_cancer" rel="nofollow" title="Recent changes in pages linked from this page [k]" accesskey="k">Related changes</a></li><li id="t-specialpages" class="mw-list-item"><a href="/wiki/Special:SpecialPages" title="A list of all special pages [q]" accesskey="q">Special pages</a></li><li id="t-print" class="mw-list-item"><a href="javascript:print();" rel="alternate" title="Printable version of this page [p]" accesskey="p">Printable version</a></li><li id="t-permalink" class="mw-list-item"><a href="/wiki/index.php?title=Breast_cancer&oldid=979686" title="Permanent link to this revision of this page">Permanent link</a></li><li id="t-info" class="mw-list-item"><a href="/wiki/index.php?title=Breast_cancer&action=info" title="More information about this page">Page information</a></li><li id="t-cite" class="mw-list-item"><a href="/wiki/index.php?title=Special:CiteThisPage&page=Breast_cancer&id=979686&wpFormIdentifier=titleform" title="Information on how to cite this page">Cite this page</a></li></ul> </div> </nav> </div> </div> <footer id="footer" class="mw-footer" role="contentinfo" > <ul id="footer-info"> <li id="footer-info-lastmod"> This page was last modified 12:10, 14 September 2024.</li> <li id="footer-info-copyright">CZ is free. All written content is available under the <a href="https://citizendium.org/wiki/Creative_Commons_CC-by-sa_3.0">Creative Commons-Attribution-ShareAlike 3.0 Unported license</a> or any later. Written content that originated in part from Wikipedia is also available under <a class="external" rel="nofollow" href="https://creativecommons.org/licenses/by-nc-sa/4.0/">Creative Commons Attribution-NonCommercial-ShareAlike</a>. <a href="https://citizendium.org/wiki/Help:Index">Help</a> • <a href="https://citizendium.org/wiki/CZ:Financial_report">Financial Report</a> • Follow Citizendium on <a href="https://twitter.com/TheCitizendium">Twitter</a> • <a href="https://www.facebook.com/citizendium">Facebook</a></li> </ul> <ul id="footer-places"> <li id="footer-places-privacy"><a href="/wiki/CZ:Privacy_policy">Privacy policy</a></li> <li id="footer-places-about"><a href="/wiki/CZ:About">About Citizendium</a></li> <li id="footer-places-disclaimer"><a href="/wiki/CZ:General_disclaimer">Disclaimers</a></li> </ul> <ul id="footer-icons" class="noprint"> <li id="footer-copyrightico"><a href="https://creativecommons.org/licenses/by-nc-sa/4.0/"><img src="/wiki/resources/assets/licenses/cc-by-nc-sa.png" alt="Creative Commons Attribution-NonCommercial-ShareAlike" width="88" height="31" loading="lazy"/></a></li> <li id="footer-poweredbyico"><a href="https://www.mediawiki.org/"><img src="/wiki/resources/assets/poweredby_mediawiki_88x31.png" alt="Powered by MediaWiki" srcset="/wiki/resources/assets/poweredby_mediawiki_132x47.png 1.5x, /wiki/resources/assets/poweredby_mediawiki_176x62.png 2x" width="88" height="31" loading="lazy"/></a></li> </ul> </footer> <script>(RLQ=window.RLQ||[]).push(function(){mw.config.set({"wgBackendResponseTime":636});});</script> </body>  </html>